var title_f15_21_15696="Vascular malformation 9de";
var content_f15_21_15696=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Right and left uterine angiograms",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 275px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Right (A) and left (B) uterine angiograms before uterine artery embolization shows increased vascularity and an arteriovenous malformation (arrow in A) in the uterus with dilated uterine arteries (arrow in B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_21_15696=[""].join("\n");
var outline_f15_21_15696=null;
var title_f15_21_15697="Ulceroglandular tularemia";
var content_f15_21_15697=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ulceroglandular tularemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The primary inoculation site in this patient with ulceroglandular tularemia is an ulcerated nodule that is accompanied by lymphadenopathy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles V Sanders. (The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_21_15697=[""].join("\n");
var outline_f15_21_15697=null;
var title_f15_21_15698="Patient information: Benign prostatic hyperplasia (enlarged prostate) (The Basics)";
var content_f15_21_15698=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15355\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/32/37382\">",
"         Prostate gland",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/30/12768\">",
"          Rectal exam",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/8/22658\">",
"         Patient information: Urinary incontinence (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?27/51/28467\">",
"         Patient information: Benign prostatic hyperplasia (BPH) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Benign prostatic hyperplasia (enlarged prostate) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/benign-prostatic-hyperplasia-enlarged-prostate-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H295530323\">",
"      <span class=\"h1\">",
"       What is benign prostatic hyperplasia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;&ldquo;Benign prostatic hyperplasia&rdquo; is the medical term for an enlarged prostate. The prostate is a gland that surrounds the urethra (the tube that carries urine from the bladder out through the penis) (",
"      <a class=\"graphic graphic_figure graphicRef65675 \" href=\"UTD.htm?36/32/37382\">",
"       figure 1",
"      </a>",
"      ). This gland often gets bigger in men as they get older.",
"     </p>",
"     <p>",
"      Benign prostatic hyperplasia, also called &ldquo;BPH,&rdquo; is a common problem. It has nothing to do with prostate cancer. In fact, the word &ldquo;benign&rdquo; means &ldquo;not cancer.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H295530330\">",
"      <span class=\"h1\">",
"       What are the symptoms of BPH?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many men with BPH have no symptoms at all. When symptoms do occur, they can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Needing to urinate often, especially at night",
"       </li>",
"       <li>",
"        Having trouble starting to urinate (this means that you might have to wait or strain before urine will come out)",
"       </li>",
"       <li>",
"        Having a weak urine stream",
"       </li>",
"       <li>",
"        Leaking or dribbling urine",
"       </li>",
"       <li>",
"        Feeling as though your bladder is not empty even after you urinate",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In rare cases, BPH makes it so a man cannot urinate at all. This is a serious problem. If you cannot urinate at all, call your doctor right away. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H295530337\">",
"      <span class=\"h1\">",
"       Is there a test for BPH?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse can check for BPH by doing a rectal exam. That means that he or she will put a finger into your anus to check how big your prostate is and what it feels like (",
"      <a class=\"graphic graphic_figure graphicRef80412 \" href=\"UTD.htm?12/30/12768\">",
"       figure 2",
"      </a>",
"      ). Your doctor or nurse might also do urine or blood tests to see if your symptoms might be caused by another problem, such as a bladder infection.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H295530344\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You may be able to improve your BPH symptoms by:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Reducing the amount of fluid you drink, especially just before bed",
"       </li>",
"       <li>",
"        Limiting the amount of alcohol and caffeine you drink. These drinks can make you urinate more often.",
"       </li>",
"       <li>",
"        Avoiding cold and allergy medicines that contain antihistamines or decongestants. These medicines can make the symptoms of BPH worse.",
"       </li>",
"       <li>",
"        Doing something doctors call &ldquo;double voiding.&rdquo; That means that after you empty your bladder, you wait a moment, relax, and try to urinate again.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H295530351\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have symptoms like the ones listed above, see your doctor or nurse to find out if BPH is really what's causing them. Those symptoms can be caused by other problems, so it's important to have them checked out.",
"     </p>",
"     <p>",
"      If you do have BPH, your doctor or nurse can offer you different treatment options. But you don't have to get treated if your symptoms do not bother you. Unless you lose the ability to urinate completely, leaving BPH untreated will not hurt you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H295530358\">",
"      <span class=\"h1\">",
"       How is BPH treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments options include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Watchful waiting",
"        </strong>",
"        &ndash; Watchful waiting means that you wait to see if your symptoms change, but you don't have treatment right away. Men who choose this option can decide to try treatment later if their symptoms get worse, or if their symptoms start to bother them more.",
"       </li>",
"       <li>",
"        <strong>",
"         Medicines",
"        </strong>",
"        &ndash; There are two main types of medicines to treat BPH. One type relaxes the muscles that surround the urethra. The other type keeps the prostate from growing more or even helps the prostate shrink. In some cases, doctors suggest taking both types of medicine at the same time.",
"       </li>",
"       <li>",
"        <strong>",
"         Surgery",
"        </strong>",
"        &ndash; Surgery to treat BPH works by removing some of the prostate, or by causing the prostate to shrink. There are several surgeries to choose from.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H295530365\">",
"      <span class=\"h1\">",
"       How do I choose which treatment to have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The right treatment for you will depend on:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        How much your symptoms bother you",
"       </li>",
"       <li>",
"        How you feel about the different treatment options",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If your symptoms don't bother you very much, you may not need any treatment. On the other hand, if your symptoms do bother you, you probably should get treated.",
"     </p>",
"     <p>",
"      Doctors often suggest trying medicines first to see if they help. If medicines don't do enough, surgery is also an option. As you think about your choices, remember that most treatments have a downside. Medicines can cause side effects, for example. And surgery usually has some risks and can cause problems with sex and other side effects.",
"     </p>",
"     <p>",
"      When you're thinking about which treatment to have, ask your doctor or nurse these questions:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        How likely is it that this treatment will improve my symptoms?",
"       </li>",
"       <li>",
"        What are the risks or side effects of this treatment?",
"       </li>",
"       <li>",
"        What happens if I don't have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H295530470\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/8/22658?source=see_link\">",
"       Patient information: Urinary incontinence (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/51/28467?source=see_link\">",
"       Patient information: Benign prostatic hyperplasia (BPH) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?15/21/15698?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15355 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-49B032D4AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_21_15698=[""].join("\n");
var outline_f15_21_15698=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H295530323\">",
"      What is benign prostatic hyperplasia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H295530330\">",
"      What are the symptoms of BPH?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H295530337\">",
"      Is there a test for BPH?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H295530344\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H295530351\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H295530358\">",
"      How is BPH treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H295530365\">",
"      How do I choose which treatment to have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H295530470\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15355\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/32/37382\">",
"      Prostate gland",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/30/12768\">",
"       Rectal exam",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/51/28467?source=related_link\">",
"      Patient information: Benign prostatic hyperplasia (BPH) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/8/22658?source=related_link\">",
"      Patient information: Urinary incontinence (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_21_15699="Testosterone preparations";
var content_f15_21_15699=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F53955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F53955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 613px\">",
"   <div class=\"ttl\">",
"    Structure of the different testosterone preparations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 593px; height: 469px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Structure of the testosterone preparations available for the treatment of men with hypogonadism.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_21_15699=[""].join("\n");
var outline_f15_21_15699=null;
var title_f15_21_15700="Ciprofloxacin (otic): Patient drug information";
var content_f15_21_15700=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ciprofloxacin (otic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/20/27971?source=see_link\">",
"     see \"Ciprofloxacin (otic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/48/38658?source=see_link\">",
"     see \"Ciprofloxacin (otic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9611245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cetraxal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691827",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat ear infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701810",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ciprofloxacin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the ear only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Warm solution in hands 1 to 2 minutes before putting drops in ear.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695296",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Lie on your side with problem ear up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pull the outer ear outward and upward.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695238",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put drops in ear without touching dropper to ear. Stay on side for 1 minute.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699575",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store unused containers in foil pouch until use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11586 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C9EBEEE8B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_21_15700=[""].join("\n");
var outline_f15_21_15700=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611245\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030435\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030434\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030439\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030440\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030442\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030437\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030438\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030443\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030444\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/7/26740?source=related_link\">",
"      Ciprofloxacin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/39/36468?source=related_link\">",
"      Ciprofloxacin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/50/6947?source=related_link\">",
"      Ciprofloxacin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/20/27971?source=related_link\">",
"      Ciprofloxacin (otic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/48/38658?source=related_link\">",
"      Ciprofloxacin (otic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/5/20570?source=related_link\">",
"      Ciprofloxacin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/11/17590?source=related_link\">",
"      Ciprofloxacin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/11/44216?source=related_link\">",
"      Ciprofloxacin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_21_15701="Vitamin K (phytonadione): Pediatric drug information";
var content_f15_21_15701=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vitamin K (phytonadione): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"    see \"Vitamin K (phytonadione): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/4/38980?source=see_link\">",
"    see \"Vitamin K (phytonadione): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F209759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mephyton&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F209760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      AquaMEPHYTON&reg;;",
"     </li>",
"     <li>",
"      Konakion;",
"     </li>",
"     <li>",
"      Mephyton&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1061083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nutritional Supplement",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vitamin, Fat Soluble",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11444748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adequate intake: 2 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Vitamin K deficiency bleeding (formerly known as hemorrhagic disease of the newborn):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prophylaxis: I.M.:",
"     <b>",
"      Note:",
"     </b>",
"     Administer within 1 hour of birth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AAP recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Birth weight &lt;1000 g: 0.3 mg/kg (Costakos, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Birth weight  &ge;1000 g: 0.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Term neonate: 0.5-1 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Alternative dosing: GA &lt;32 weeks: 0.2 mg; may repeat dose for prolonged prothrombin time or clinical signs of bleeding (Clarke, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment: SubQ, I.M.: 1-2 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1061078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"      see \"Vitamin K (phytonadione): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ route is preferred; I.V. and I.M. routes should be restricted for situations when the SubQ route is not feasible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral anticoagulant overdose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     No bleeding, rapid reversal needed, patient will require further oral anticoagulant therapy: SubQ, I.V.: 0.5-2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     No bleeding, rapid reversal needed, patient will",
"     <b>",
"      not",
"     </b>",
"     require further oral anticoagulant therapy: SubQ, I.V.: 2-5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Significant bleeding, not life-threatening: SubQ, I.V.: 0.5-2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Significant bleeding, life-threatening: I.V.: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents and Adults: SubQ, I.V.: 2.5-10 mg/dose (rarely up to 25-50 mg has been used in adults); may repeat in 6-8 hours if given by SubQ, I.V. route; may repeat 12-48 hours after oral route",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Vitamin K deficiency due to drugs, malabsorption, or decreased synthesis of vitamin K:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 2.5-5 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     SubQ, I.M., I.V.: 1-2 mg/dose as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 2.5-25 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     SubQ, I.M., I.V.: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Minimum daily requirement: Oral: Not well established",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 1-5 mcg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 0.03 mcg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adequate intake:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-6 months: 2 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7-12 months: 2.5 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years: 30 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years: 55 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-13 years: 60 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     14-18 years: 75 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults, male: 120 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults, female: 90 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pregnant, &lt;18 years of age: 75 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pregnant, &gt;19 years of age: 90 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Breast-feeding, &lt;18 years of age: 75 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Breast-feeding, &gt;19 years of age: 90 mcg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F209741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, aqueous colloidal: 1 mg/0.5 mL (0.5 mL) [contains benzyl alcohol, polyoxyethylated castor oil]; 10 mg/mL (1 mL) [contains benzyl alcohol, polyoxyethylated castor oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, aqueous colloidal [preservative free]: 1 mg/0.5 mL (0.5 mL) [contains polysorbate 80, propylene glycol 10.4 mg/0.5 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 100 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mephyton&reg;: 5 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F209727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1061087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May be administered with or without food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: SubQ administration is the preferred method; for I.V. administration, dilute in 5-10 mL I.V. fluid (D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS) (maximum concentration: 10 mg/mL); infuse over 15-30 minutes; maximum rate of infusion: 1 mg/minute",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F2876773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Stable at room temperature; protect from light",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1061086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of hypoprothrombinemia caused by vitamin K deficiency or anticoagulant-induced hypoprothrombinemia; vitamin K deficiency bleeding (VKDB) of the newborn",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F209808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Mephyton&reg; may be confused with melphalan, methadone",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F209807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Cyanosis, flushing, hyper-/hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Dizziness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Erythematous skin eruptions, pruritus, scleroderma-like lesions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Hyperbilirubinemia (newborn; greater than recommended doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abnormal taste",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Local: Injection site reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Diaphoresis, hypersensitivity reactions, nonimmunologic anaphylaxis (formerly known as anaphylactoid reaction), sweating",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1061092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to phytonadione or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1061077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe reactions resembling anaphylaxis or hypersensitivity have occurred rarely during or immediately after I.V. administration (even with proper dilution and rate of administration)",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     and with I.M. administration; restrict I.V. and I.M. administration for situations where the subcutaneous route is not feasible.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1061076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ineffective in hereditary hypoprothrombinemia and hypoprothrombinemia caused by severe liver disease. In neonates, severe hemolytic anemia and hyperbilirubinemia have been reported rarely following large doses (10-20 mg) of phytonadione. Injection contains 0.9% benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein-binding sites; injection is safe in neonates when used in appropriate doses. Injection may also contain polysorbate 80 (Tween 80&reg;) which may cause allergic reactions in susceptible individuals. In premature neonates, thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported after receiving parenteral products containing polysorbate 80 (Alade, 1986;",
"     <i>",
"      MMWR",
"     </i>",
"     , 1984). Infusion of polysorbate 80-containing solutions through polyvinyl chloride tubing may cause DEHP to leach into the solution; in immature animals, exposure to DEHP may adversely affect the development of the male reproductive tract.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F209735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mineral Oil: May decrease the serum concentration of Phytonadione. Specifically, mineral oil may decrease the absorption of phytonadione.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orlistat: May decrease the serum concentration of Vitamins (Fat Soluble). Management: Administer oral fat soluble vitamins at least 2 hours before or after the administration of orlistat.  Similar precautions do not apply to parenterally administered fat soluble vitamins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Phytonadione may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F209737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10916304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1061082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     PT, INR (if applicable)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1061075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cofactor in the liver synthesis of clotting factors (II, VII, IX, X)",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1061090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Blood coagulation factors increase within 6-12 hours after oral doses and within 1-2 hours following parenteral administration; after parenteral administration prothrombin time may become normal after 12-14 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1061091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: From the intestines in the presence of bile",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Rapidly in the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In bile and urine",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1061093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Phytonadione is more effective and is preferred to other vitamin K preparations in the presence of impending hemorrhage; oral absorption depends on the presence of bile salts",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F209746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 1 mg/mL oral suspension may be made with tablets. Crush six 5 mg tablets in a mortar and reduce to a fine powder. Add 5 mL each of water and methylcellulose 1% and mix to a uniform paste. Mix while adding sorbitol in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     30 mL; transfer to a calibrated bottle, rinse mortar with sorbitol, and add quantity of sorbitol sufficient to make 30 mL. Label \"shake well\" and \"refrigerate\". Stable for 3 days.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 3rd ed, Cincinnati, OH: Harvey Whitney Books Co, 1997.",
"    </div>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Note:",
"     </b>",
"     The parenteral formulation may also be used for small oral doses (eg, 1 mg) or situations in which tablets cannot be swallowed (Crowther, 2000; O&rsquo;Connor, 1986).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alade SL, Brown RE, and Paquet A Jr, \"Polysorbate 80 and E-Ferol Toxicity,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1986, 77(4):593-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/21/15701/abstract-text/3960626/pubmed\" id=\"3960626\" target=\"_blank\">",
"        3960626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Fetus and Newborn, \"Controversies Concerning Vitamin K and the Newborn. American Academy of Pediatrics Committee on Fetus and Newborn,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2003, 112(1 Pt 1):191-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/21/15701/abstract-text/12837888/pubmed\" id=\"12837888\" target=\"_blank\">",
"        12837888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Nutrition, \"Micronutrients: Vitamin K,\"",
"      <i>",
"       Pediatric Nutrition Handbook",
"      </i>",
"      , 6th ed, Kleinman RE, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009, 469.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control (CDC), \"Unusual Syndrome With Fatalities Among Premature Infants: Association With a New Intravenous Vitamin E Product,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 1984, 33(14):198-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/21/15701/abstract-text/6423951/pubmed\" id=\"6423951\" target=\"_blank\">",
"        6423951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clarke P, Mitchell SJ, Wynn R, et al, \"Vitamin K Prophylaxis for Preterm Infants: A Randomized, Controlled Trial of 3 Regimens,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 118(6):e1657-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/21/15701/abstract-text/17101711/pubmed\" id=\"17101711\" target=\"_blank\">",
"        17101711",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Costakos DT, Greer FR, Love LA, et al, \"Vitamin K Prophylaxis for Premature Infants: 1 mg Versus 0.5 mg,\"",
"      <i>",
"       Am J Perinatol",
"      </i>",
"      , 2003, 20(8):485-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/21/15701/abstract-text/14703597/pubmed\" id=\"14703597\" target=\"_blank\">",
"        14703597",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Michelson AD, Bovill E, Monagle P, et al, &ldquo;Antithrombic Therapy in Children,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 1998, 114(5 Suppl):748S-69S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/21/15701/abstract-text/9822076/pubmed\" id=\"9822076\" target=\"_blank\">",
"        9822076",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12704 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-88.81.100.162-2094B74F85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_21_15701=[""].join("\n");
var outline_f15_21_15701=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709210\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209759\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209760\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061083\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11444748\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061078\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209741\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209727\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061087\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2876773\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061086\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209808\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209807\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061092\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061077\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061076\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299879\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209735\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209737\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10916304\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061082\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061075\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061090\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061091\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061093\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209746\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12704\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12704|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=related_link\">",
"      Vitamin K (phytonadione): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/4/38980?source=related_link\">",
"      Vitamin K (phytonadione): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_21_15702="Clonidine and chlorthalidone: Drug information";
var content_f15_21_15702=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clonidine and chlorthalidone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/28/15813?source=see_link\">",
"    see \"Clonidine and chlorthalidone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F153568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Clorpres&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F153580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha;",
"      <sub>",
"       2",
"      </sub>",
"      -Adrenergic Agonist",
"     </li>",
"     <li>",
"      Diuretic, Thiazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F153569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypertension: Oral: One tablet (clonidine 0.1-0.3 mg/chlorthalidone 15 mg per tablet) 1-2 times daily; maximum: 0.6 mg clonidine and 30 mg chlorthalidone daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F153570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May benefit from lower initial dose; see individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15795880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No specific dosage adjustments provided in manufacturer's labeling; use with caution in severe renal disease.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15795881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No specific dosage adjustments provided in manufacturer's labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F153559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     0.1: Clonidine hydrochloride 0.1 mg and chlorthalidone 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     0.2: Clonidine hydrochloride 0.2 mg and chlorthalidone 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     0.3: Clonidine hydrochloride 0.3 mg and chlorthalidone 15 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F153549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F153561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F153585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Combipres may be confused with Catapres&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F153578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reactions which follow have been reported with the combination product; see individual drug agents for additional adverse reactions that may be expected from each agent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Drowsiness (33%), dizziness (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Xerostomia (40%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Sedation (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Constipation (10%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F15832569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Hypersensitivity to chlorthalidone or other sulfonamide-derived drugs",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10512383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bradycardia: Clonidine may cause dose-dependent reductions in heart rate; use with caution in patients with pre-existing bradycardia or those predisposed to developing bradycardia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: Clonidine may cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte disturbances: Chlorthalidone may cause hypokalemia, hypochloremic alkalosis, or hyponatremia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Chlorthalidone may cause photosensitization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rash: Patients using transdermal clonidine who have experienced allergic reactions (eg, generalized rash, urticaria, angioedema) may also experience rash and similar reactions following subsequent substitution of oral therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, loop diuretics (except ethacrynic acid), and chlorthalidone. Use in patients with thiazide or sulfonamide allergy is specifically contraindicated in product labeling; however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use clonidine with caution in patients with severe coronary insufficiency, including recent MI and conduction disturbances, such as sinus node dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cerebrovascular disease: Use clonidine with caution in patients with cerebrovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use chlorthalidone with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: Chlorthalidone can precipitate gout in certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use chlorthalidone with caution in patients with severe hepatic dysfunction; in cirrhosis, avoid electrolyte and acid/base imbalances that may lead to hepatic coma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercalcemia: Thiazide diuretics may decrease renal calcium excretion; consider avoiding use of chlorthalidone in patients with hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Use chlorthalidone with caution in patients with hypokalemia; correct before initiating therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Avoid chlorthalidone in severe renal disease (ineffective); use clonidine with caution in patients with chronic renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic lupus erythematosus (SLE): Chlorthalidone is structurally related to thiazide diuretics which have been associated with SLE exacerbation or activation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Agents with SA/AV nodal blocking properties: Use clonidine with caution in patients concurrently receiving agents known to reduce SA node function and/or AV nodal conduction (eg, digoxin, diltiazem, metoprolol, verapamil); may increase risk of serious bradycardia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants: Sedating effects of clonidine may be potentiated when used with other CNS-depressant drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: Discontinue oral immediate release formulations within 4 hours of surgery, then restart as soon as possible afterwards.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Gradual withdrawal of clonidine is needed (taper gradually over 2-4 days to avoid rebound hypertension) if drug needs to be stopped. Patients should be instructed about abrupt discontinuation (causes rapid increase in BP and symptoms of sympathetic overactivity).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F153555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Alpha2-Antagonist): May diminish the antihypertensive effect of Alpha2-Agonists. Management: Consider avoiding concurrent use.  If these combinations cannot be avoided, monitor for decreased effects of alpha2-agonists if an alpha2-antagonist is initiated/dose increased, or increased effects if an alpha2-antagonist is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Alpha2-Agonists may enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn.  Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): CloNIDine may enhance the AV-blocking effect of Calcium Channel Blockers (Nondihydropyridine). Sinus node dysfunction may also be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: CloNIDine may enhance the AV-blocking effect of Cardiac Glycosides. Sinus node dysfunction may also be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Alpha2-Agonists may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the adverse/toxic effect of CloNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May diminish the antihypertensive effect of Alpha2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May diminish the antihypertensive effect of Alpha2-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F153556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F153566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to Clonidine monograph.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F153572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Clonidine: Enters breast milk/not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Chlorthalidone: Enters breast milk/compatible",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F153565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Clorpres Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1-15 mg (100): $233.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2-15 mg (100): $312.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3-15 mg (100): $382.36",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F15832640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum electrolytes, renal function; blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F153563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/21/15702/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaplan NM and Sever PS, &ldquo;Combination Therapy: A Key to Comprehensive Patient Care,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 1997, 10(7 Pt 2):127S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/21/15702/abstract-text/9231887/pubmed\" id=\"9231887\" target=\"_blank\">",
"        9231887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moser M and Black HR, &ldquo;The Role of Combination Therapy in the Treatment of Hypertension,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 1998, 11(6 Pt 2):73S-8S, 95S-100S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/21/15702/abstract-text/9655566/pubmed\" id=\"9655566\" target=\"_blank\">",
"        9655566",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8716 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-AC55A795B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_21_15702=[""].join("\n");
var outline_f15_21_15702=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153568\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153580\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153569\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153570\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795880\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795881\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153559\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153549\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153561\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153585\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153578\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15832569\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512383\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299068\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153555\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153556\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153566\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153572\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153565\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15832640\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153563\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8716\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8716|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/28/15813?source=related_link\">",
"      Clonidine and chlorthalidone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_21_15703="Functional PET imaging for metastatic GI neuroendocrine tumor";
var content_f15_21_15703=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F81388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F81388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Functional PET imaging techniques for metastatic gastrointestinal tract neuroendocrine tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 584px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Fused 18F-dihydroxy-phenyl-alanine (18F-DOPA) positron emission tomography (PET)/computed tomography scan, (B) somatostatin receptor scintigraphy, (C) 18F-DOPA PET, and (D) 11C-5-hydroxy-tryptophan (11C-5-HTP) PET of an 80-year-old male patient with metastatic neuroendocrine tumor of the gastrointestinal tract.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Koopmans KP, Neels OC, Kema IP, et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 2008; 26:1489. Reprinted with permission. Copyright &copy; 2008 American Society of Clinical Oncology. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_21_15703=[""].join("\n");
var outline_f15_21_15703=null;
var title_f15_21_15704="Embryonal rhabdomyosarcoma";
var content_f15_21_15704=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Embryonal rhabdomyosarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Classic embryonal rhabdomyosarcoma (RMS) is composed of typical rhabdomyoblasts arranged in sheets and large nests, with infrequent intermixed fusiform cells. The typical rhabdomyoblast has moderate to deeply eosinophilic cytoplasm, representing poorly formed myofilaments. (H&amp;E, 200x original magnification).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_21_15704=[""].join("\n");
var outline_f15_21_15704=null;
var title_f15_21_15705="Yellow fever";
var content_f15_21_15705=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Yellow fever",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/21/15705/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/21/15705/contributors\">",
"     Thomas P Monath, MD, FACP, FASTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/21/15705/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/21/15705/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/21/15705/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/21/15705/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/21/15705/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Yellow fever is a mosquito-borne viral hemorrhagic fever with a high case fatality rate. Clinical manifestations include hepatic dysfunction, renal failure, coagulopathy, and shock. Travelers to tropical regions of South America and sub-Saharan Africa where the disease is endemic are at risk for acquisition of infection and require immunization.",
"   </p>",
"   <p>",
"    Issues related to virology, pathogenesis, epidemiology, clinical manifestations, diagnosis, treatment, and prevention of yellow fever will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VIROLOGY, PATHOGENESIS AND HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Yellow fever is the prototype member of the family Flaviviridae, a group of small (40 to 60 nm), enveloped, positive-sense, single-stranded RNA viruses that replicate in the cytoplasm of infected cells. Yellow fever virus is a single serotype and is antigenically conserved, so the vaccine protects against all strains of the virus. At the nucleotide sequence level, it is possible to distinguish seven major genotypes representing West Africa (two genotypes), Central-East Africa and Angola (three genotypes), and South America (two genotypes) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Humans are highly susceptible to infection and disease. Most non-human primate species are susceptible to infection, and some species of non-human primates develop clinical manifestations.",
"   </p>",
"   <p>",
"    An infected female mosquito inoculates approximately 1000 to 100,000 virus particles intradermally during blood feeding. Virus replication begins at the site of inoculation, probably in dendritic cells in the epidermis, and spreads through lymphatic channels to regional lymph nodes. Lymphoid cells, particularly monocyte-macrophages and large histiocytes, appear to be the preferred cell types for primary replication. The virus reaches other organs via the lymph and then the bloodstream, seeding other tissues. Large amounts of virus are produced in the liver and spleen and released into the blood. During the viremic phase (days three to six), infection may be transmitted to blood-feeding mosquitoes.",
"   </p>",
"   <p>",
"    Yellow fever is characterized by hepatic dysfunction, renal failure, coagulopathy, and shock [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. The midzone of the liver lobule is principally affected, with sparing of cells bordering the central vein and portal tracts [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/7\">",
"     7",
"    </a>",
"    ]. Viral antigen localizes to the midzone, indicating that it is the site of direct viral injury. Very high virus loads have been found in the liver and spleen of fatal cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Injury to hepatocytes is characterized by eosinophilic degeneration with condensed nuclear chromatin (Councilman bodies), rather than by the ballooning and rarefaction necrosis seen in viral hepatitis. Liver cell death is due to apoptosis. Hepatocytes in the midzone of the liver lobule express Fas ligand, and lymphocytes infiltrating the liver mediate apoptosis. Inflammatory cells, mainly CD4+ cells, are present in low numbers; smaller numbers of NK and CD8+ cells are present [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. There is no disruption of the reticular architecture of the liver. In nonfatal cases, healing is complete without postnecrotic fibrosis. In fatal cases, approximately 80 percent of hepatocytes undergo coagulative necrosis.",
"   </p>",
"   <p>",
"    Renal damage is characterized by eosinophilic degeneration and fatty change of renal tubular epithelium without inflammation. These findings are believed to be a result of both direct viral injury and nonspecific changes due to hypotension and the hepatorenal syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Focal injury to the myocardium, characterized by cell degeneration and fatty change, is the result of viral replication.",
"   </p>",
"   <p>",
"    The hemorrhagic diathesis in yellow fever is due to decreased synthesis of vitamin K-dependent coagulation factors by the liver, disseminated intravascular coagulation, and platelet dysfunction.",
"   </p>",
"   <p>",
"    The late phase of the disease is characterized by circulatory shock. The underlying mechanism may be cytokine dysregulation, as in the sepsis syndrome. In a series of patients with fatal yellow fever, levels of pro-inflammatory cytokines (interleukin [IL]-6, IL-1 receptor antagonist, TNF-alpha, and interferon-inducible protein-10) were elevated compared with patients with nonfatal yellow fever [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/11\">",
"     11",
"    </a>",
"    ]. Patients dying of yellow fever have cerebral edema at autopsy, probably the result of microvascular dysfunction.",
"   </p>",
"   <p>",
"    Some nonhuman primate species develop fatal infection with features similar to the disease in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/5\">",
"     5",
"    </a>",
"    ]. A model of yellow fever infection in hamsters has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Clinical, immunologic, and pathologic features resemble human infection, suggesting that this model might serve to increase the understanding of the pathogenesis of infection and to explore possible treatments. Interferon deficient mice are also susceptible to viscerotropic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Yellow fever occurs in tropical regions of sub-Saharan Africa and South America; it is an epidemic disease problem of considerable magnitude [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The incidence of endemic disease is not well established, but approximately 1 percent of individuals with severe hepatitis in endemic areas of Africa may be caused by yellow fever [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of yellow fever in Africa varies widely because of the occurrence of epidemics in which humans serve as the viremic host for infection of Aedes mosquito vectors (eg, in Ethiopia in 1960-1962, Nigeria in 1987) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/15\">",
"     15",
"    </a>",
"    ]. While official records have documented up to 5000 cases in such epidemic years, the true incidence likely approached &gt;100,000 cases. Mosquito-borne epidemics in Africa occur where large human populations reside in high density and immunization coverage is low. Human-to-human transmission in the absence of the mosquito does not occur.",
"   </p>",
"   <p>",
"    Fewer cases occur in South America than in Africa because transmission occurs from enzootic sources (principally from monkey to human via mosquito vectors), the vector density is relatively low, and vaccination coverage is relatively high (80 to 90 percent in endemic areas of South America). In typical years, there are several hundred cases officially notified, but in epidemic years up to 5000 cases are reported.",
"   </p>",
"   <p>",
"    In both Africa and South America only a small proportion of cases are officially recorded because the disease often occurs in remote areas, recognition of outbreaks is delayed, and diagnostic facilities are limited. In Africa, reports of outbreaks in the 1980s noted the incidence of yellow fever infection to be 20 to 40 percent, the incidence of severe disease to be 3 to 5 percent, and the case fatality rate to be 20 to 30 percent. In contrast, case fatality rates in South America are consistently 50 to 60 percent. It is uncertain if these disparities reflect reporting artifact, a real difference in virus strain virulence,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    differing genetic susceptibility of the human populations. These historical epidemiological descriptions of the medical impact of yellow fever may be changing as use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/13/14550?source=see_link\">",
"     yellow fever vaccine",
"    </a>",
"    is expanding.",
"   </p>",
"   <p>",
"    Among expatriates and travelers to Africa and South America, yellow fever has been rare since the introduction of vaccination after World War II. Since that time, 10 cases have been recorded [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/8,18-22\">",
"     8,18-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Transmission cycles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary transmission cycle involves monkeys and daytime biting mosquitoes (Aedes species in Africa; Haemagogus species in South America).",
"   </p>",
"   <p>",
"    In Africa a wide array of Aedes vectors are responsible for transmission. During the rainy season the virus circulates via mosquitoes in the savanna vegetational zone in proximity to human settlements. Both humans and nonhuman primates can be hosts in the transmission cycle, and the rate of virus transmission may accelerate to reach epidemic levels. Aedes aegypti, a common domestic mosquito that can breed in containers used to store potable water in heavily settled areas, is capable of serving as an epidemic vector with humans as the intermediate viremic hosts (so-called \"urban yellow fever\").",
"   </p>",
"   <p>",
"    In South America, the larval development of mosquitoes occurs in areas, such as tree holes containing rainwater. Persons entering forested areas are at risk of infection (so-called \"jungle yellow fever\"); this accounts for the predominance of cases among young males engaged in forest clearing and agriculture. In the 1970s, the Aedes aegypti mosquito reinvaded areas of South America where it previously had been eradicated, increasing the risk that urban yellow fever may reemerge. The first well-documented instance of an urban-cycle epidemic since 1942 occurred in Paraguay in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical spectrum of yellow fever includes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Subclinical infection",
"     </li>",
"     <li>",
"      Abortive, nonspecific febrile illness without jaundice",
"     </li>",
"     <li>",
"      Life-threatening disease with fever, jaundice, renal failure, and hemorrhage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Yellow fever affects all ages, but disease severity and lethality is highest in the elderly. The onset of illness appears abruptly three to six days after the bite of an infected mosquito. The classical illness is characterized by three stages:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Period of infection",
"     </li>",
"     <li>",
"      Period of remission",
"     </li>",
"     <li>",
"      Period of intoxication",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Period of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The period of infection consists of viremia, which lasts for three to four days. The patient is febrile and complains of generalized malaise, headache, photophobia, lumbosacral pain, pain in the lower extremities (particularly the knee joints), myalgia, anorexia, nausea, vomiting, restlessness, irritability, and dizziness [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/25\">",
"     25",
"    </a>",
"    ]. Symptoms and signs are relatively nonspecific; at this phase it is virtually impossible to distinguish yellow fever from other acute infections.",
"   </p>",
"   <p>",
"    On physical examination the patient appears acutely ill with flushed skin, reddening of the conjunctivae and gums, and epigastric tenderness. Enlargement of the liver with tenderness may be present. The tongue is characteristically red at the tip and sides with a white coating in the center. The pulse rate is slow relative to the height of the fever (Faget's sign). The temperature is typically 39&ordm;C but may rise as high as 41&ordm;C.",
"   </p>",
"   <p>",
"    Laboratory abnormalities include leukopenia (1500 to 2500 per microL) with relative neutropenia; leukopenia occurs rapidly after the onset of illness. Serum transaminase levels start to rise 48 and 72 hours after onset of illness, prior to the appearance of jaundice. The degree of liver enzyme abnormalities at this stage may predict the severity of hepatic dysfunction later in the illness [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Period of remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;A period of remission lasting up to 48 hours may follow the period of infection, characterized by the abatement of fever and symptoms. Patients with abortive infections recover at this stage. Approximately 15 percent of individuals infected with yellow fever virus enter the third stage of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Period of intoxication",
"    </span>",
"    &nbsp;&mdash;&nbsp;The period of intoxication begins on the third to sixth day after the onset of infection with return of fever, prostration, nausea, vomiting, epigastric pain, jaundice, oliguria, and hemorrhagic diathesis. The viremia terminates at this stage and antibodies appear in the blood. This phase is characterized by variable dysfunction of multiple organs including the liver, kidneys, and cardiovascular system. Multi-organ failure in yellow fever is associated with high levels of pro-inflammatory cytokines similar to that seen in bacterial sepsis and systemic immune response syndrome (SIRS) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Hepatic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic dysfunction due to yellow fever differs from other viral hepatitides in that serum aspartate aminotransferase (AST) levels exceed those of alanine aminotransferase (ALT). This may be due to concomitant viral injury to the myocardium and skeletal muscle. The levels are proportional to disease severity. In one study, the mean AST and ALT levels in fatal cases were 2766 and 660 U, respectively, while in surviving patients with jaundice, the mean levels were 929 and 351 U [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/26\">",
"     26",
"    </a>",
"    ]. Alkaline phosphatase levels are normal or only slightly elevated. Direct bilirubin levels are typically between 5 and 10",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    with higher levels in fatal than in nonfatal cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Renal dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal damage is characterized by oliguria, azotemia, and very high levels of protein in the urine. Serum creatinine levels are three to eight times normal. In some patients who survive the hepatitic phase, renal failure predominates. Death is preceded by virtually complete anuria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemorrhage is a prominent component of the third phase of illness, including coffee-grounds hematemesis, melena, hematuria, metrorrhagia, petechiae, ecchymoses, epistaxis, oozing of blood from the gums, and bleeding from needle puncture sites. Gastrointestinal hemorrhage may contribute to circulatory collapse. Laboratory abnormalities include thrombocytopenia, prolonged prothrombin time, and global reductions in clotting factors synthesized by the liver (factors II, V, VII, IX, and X). Some patients have findings suggesting disseminated intravascular coagulation, including diminished fibrinogen and Factor VIII and the presence of fibrin split products.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Myocardial injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical significance of myocardial injury is poorly understood and probably has been underestimated in clinical studies. In some cases, acute cardiac enlargement has been documented during the course of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/28\">",
"     28",
"    </a>",
"    ]. The electrocardiogram may show sinus bradycardia without conduction defects, ST-T abnormalities, particularly elevated T waves, and extrasystoles. Bradycardia and myocarditis may contribute to hypotension, reduced perfusion, and metabolic acidosis in severe cases. Arrhythmia has been suggested to explain the rare reports of late death during convalescence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Central nervous system dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients exhibit variable signs of central nervous system (CNS) dysfunction including delirium, agitation, convulsions, stupor, and coma. In severe cases the cerebrospinal fluid is under increased pressure and may contain elevated protein but no cells. Pathologic changes include microscopic perivascular hemorrhages and edema. Given the absence of inflammatory changes suggesting viral neuroinvasion and encephalitis, CNS alterations are probably due to metabolic encephalopathy. True yellow fever viral encephalitis is exceedingly rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcome is determined during the second week after onset, at which point the patient either dies or rapidly recovers. Approximately 20 to 50 percent of patients who enter the period of intoxication succumb to the disease. Poor prognostic signs include anuria, shock, hypothermia, agitation, delirium, intractable hiccups, seizures, hypoglycemia, hyperkalemia, metabolic acidosis, Cheyne-Stokes respirations, stupor, and coma.",
"   </p>",
"   <p>",
"    Convalescence may be associated with fatigue lasting for several weeks. In some cases jaundice and serum transaminase elevations may persist for months, although such patients may have yellow fever superimposed on other hematologic or hepatic diseases. The outcome of yellow fever appears to be comparable in patients with or without hepatitis B surface antigenemia.",
"   </p>",
"   <p>",
"    Complications of yellow fever include bacterial superinfections, such as pneumonia, parotitis, and sepsis. Late deaths during convalescence occur rarely and have been attributed to myocarditis, arrhythmia, or heart failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diseases that may be confused clinically with yellow fever include dengue hemorrhagic fever, leptospirosis, louse-borne relapsing fever (Borrelia recurrentis), viral hepatitis, Rift Valley fever, Q fever, typhoid, and severe malaria. Mild yellow fever, characterized by fever, headache, malaise, and myalgias, resembles many other arboviral infections and influenza. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    Other viral hemorrhagic fevers, including Lassa, Marburg, and Ebola virus diseases, Bolivian and Argentine hemorrhagic fevers, and Congo-Crimean hemorrhagic fever, are not usually associated with jaundice.",
"   </p>",
"   <p>",
"    Diagnosis is made by serology, detection of viral genome by PCR, by viral isolation or histopathology, and immunohistochemistry on post-mortem tissues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic diagnosis is best accomplished using an enzyme linked immunosorbent assay (ELISA) for IgM. The presence of IgM antibodies in a single sample provides a presumptive diagnosis; confirmation is made by a rise in titer between paired acute and convalescent samples or a fall between early and late convalescent samples.",
"   </p>",
"   <p>",
"    Persistence of antibodies from earlier receipt of the live-attenuated vaccine can complicate interpretation of IgM results [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, cross-reactions with other flaviviruses complicate the diagnosis of yellow fever by serologic methods, particularly in Africa where multiple flaviviruses circulate. The neutralization test is more specific, but requires a specialized laboratory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Rapid diagnostic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid diagnostic tests include PCR to detect viral genome in the blood or tissue, and ELISA for determination of IgM antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/8\">",
"     8",
"    </a>",
"    ]. These tools are increasingly available in national and regional laboratories in the endemic areas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Virus isolation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virus isolation is accomplished by inoculation of mosquito or mammalian cell cultures, intracerebral inoculation of suckling mice, or intrathoracic inoculation of mosquitoes. The virus may also be recovered from postmortem liver tissue. During a yellow fever outbreak in Ivory Coast in 1982 including 90 confirmed cases, 30 percent were diagnosed by virus isolation from the blood; the majority of patients had detectable virus prior to onset of jaundice [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver biopsy during illness due to yellow fever should never be performed, since fatal hemorrhage may ensue. Postmortem histopathologic examination of the liver often demonstrates the typical features of yellow fever including midzonal necrosis. A definitive postmortem diagnosis may be made by immunocytochemical staining for yellow fever antigen in the liver, heart, spleen, or kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Virology, pathogenesis and histopathology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of yellow fever consists of supportive care; there is no specific antiviral therapy available [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/34\">",
"     34",
"    </a>",
"    ]. Management of patients may be improved by modern intensive care, but this is generally not available in remote areas where yellow fever often occurs. Travelers hospitalized after return to the United States or Europe have had fatal outcomes in spite of intensive care, demonstrating the inexorable course of severe yellow fever.",
"   </p>",
"   <p>",
"    Supportive care should include maintenance of nutrition, prevention of hypoglycemia, nasogastric suction to prevent gastric distention and aspiration, treatment of hypotension by fluid replacement and vasoactive drugs if necessary, administration of oxygen, management of metabolic acidosis, treatment of bleeding with fresh-frozen plasma, dialysis if indicated by renal failure, and treatment of secondary infections [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antiviral activity against yellow fever has been demonstrated for a number of nucleosides and plant-derived alkaloids [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/24,34,35\">",
"     24,34,35",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     Ribavirin",
"    </a>",
"    is active against yellow fever virus, but only at very high concentrations that may not be achievable clinically; further study is warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/36\">",
"     36",
"    </a>",
"    ]. In the monkey and mouse models, alpha-interferon is effective in abrogating infection if administered within 24 hours of infection and may be the treatment of choice in the event of a known exposure, for example, of an unvaccinated person exposed to wild-type yellow fever virus in the laboratory.",
"   </p>",
"   <p>",
"    The benefit of hyperimmune globulin after the onset of clinical illness is uncertain; further study is required [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/34,37,38\">",
"     34,37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A live attenuated vaccine against yellow fever was developed in 1936 (yellow fever 17D vaccine). In the United States, the vaccine (YF-VAX) is manufactured by Sanofi-Pasteur (Swiftwater, PA). Another vaccine formulation derived from a different passage series of the same vaccine virus strain, 17DD, is manufactured in Brazil [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Vaccine efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 17D vaccine produces high levels of protection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/40\">",
"     40",
"    </a>",
"    ]. Protective immunity occurs in 90 percent of individuals within 10 days after receiving the 0.5 mL subcutaneous dose, and in nearly 100 percent of individuals within three to four weeks after vaccination. The 17DD vaccine also produces similar high levels of protection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunity after a single dose is long-lasting and may provide lifetime protection. The minimum level of neutralizing antibody needed for protection has been estimated using animal models at approximately 1:40 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. The World Health Organization (WHO) international certificate of immunization is valid for 10 years; a booster 0.5 mL dose is required every 10 years for the certificate to be reissued.",
"   </p>",
"   <p>",
"    The live attenuated vaccine virus activates myeloid and plasmacytoid dendritic cells to produce a variety of proinflammatory cytokines and turn on genes that activate signaling pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/43-49\">",
"     43-49",
"    </a>",
"    ]. Overall, a marked upregulation of the innate immune system persists for about two weeks after vaccination and drives the adaptive immune response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 600 million doses of vaccines have been administered since the 17D vaccine strain was developed. Serious adverse reactions to the 17D vaccine include two syndromes, known as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/13/14550?source=see_link\">",
"     yellow fever vaccine",
"    </a>",
"    -associated neurotropic disease (YEL-AND) and yellow fever vaccine-associated viscerotropic disease (YEL-AVD). In the United States, the risks of YEL-AND and YEL-AVD in civilian travelers are estimated at 0.8 and 0.4 per 100,000 respectively, although the risk is higher in elderly individuals.",
"   </p>",
"   <p>",
"    Mild fever, headache, myalgia and malaise, and soreness at the site of inoculation can occur in the absence of liver function abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The vaccine is contraindicated for persons with known egg allergy; allergic reactions to residual egg proteins or gelatin stabilizer in yellow fever 17D vaccine occur, albeit at very low rates.",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/13/14550?source=see_link\">",
"     yellow fever vaccine",
"    </a>",
"    virus may be transmitted by transfusion of blood products. Vaccine recipients should defer blood product donation for at least two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/52\">",
"     52",
"    </a>",
"    ]. In addition, the vaccine virus may be transmitted from lactating mothers to breast-fed infants [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     YEL-AND",
"    </span>",
"    &nbsp;&mdash;&nbsp;YEL-AND refers to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/13/14550?source=see_link\">",
"     yellow fever vaccine",
"    </a>",
"    -associated neurotropic disease, an encephalitis usually caused by infection of the central nervous system with 17D virus [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/54\">",
"     54",
"    </a>",
"    ]. Onset occurs two to eight days after vaccination; the event is nearly always self-limited but rarely is associated with neurological sequelae. Definitive diagnosis is based on virus isolation, detection of viral genome by PCR, or detection of IgM antibody in cerebrospinal fluid. Cases of Guillain-Barr&eacute; and acute disseminated encephalomyelitis (ADEM) have also been described and presumably have an autoimmune etiology.",
"   </p>",
"   <p>",
"    YEL-AND has been observed in infants and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. Between 2000 and 2006, the rate of YEL-AND in the United States was 0.8 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/58\">",
"     58",
"    </a>",
"    ]. The incidence of YEL-AND is higher in the elderly; persons &ge;70 years have a rate of 2.3 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Among four cases described in adults in 2001 to 2002, all had fever and two had aphasia; cerebrospinal fluid was all positive for yellow fever-specific IgM in all patients; cultures and polymerase chain reaction were negative [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/55\">",
"     55",
"    </a>",
"    ]. Cases in infants have diminished since restriction of vaccine administration to children more than nine months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     YEL-AVD",
"    </span>",
"    &nbsp;&mdash;&nbsp;YEL-AVD refers to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/13/14550?source=see_link\">",
"     yellow fever vaccine",
"    </a>",
"    -associated viscerotropic disease, a syndrome resembling wild-type yellow fever infection that occurs in the setting of yellow fever 17D vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/54,61-63\">",
"     54,61-63",
"    </a>",
"    ]. Onset of illness occurs three to five days after vaccination with fever, malaise, jaundice, oliguria, cardiovascular instability, and hemorrhage. The case fatality rate of YEL-AVD is 63 percent and there is no specific treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/54,64,65\">",
"     54,64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The estimated incidence of YEL-AVD in the United States is 0.4 per 100,000 but may be sixfold higher among individuals &ge;60 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/59\">",
"     59",
"    </a>",
"    ]. Based on the relatively small series of cases, there appears to be a higher incidence in young adult females. In Peru, an unexplained, high incidence of YEL-AVD was reported during a mass immunization campaign (7.9 per 100,000) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There have been more deaths due to YEL-AVD than due to wild-type disease in unvaccinated travelers. This emphasizes the importance of careful assessment for vaccination need based on full understanding of disease epidemiology and travel itinerary, to avoid unnecessary risk of vaccine adverse effects but to ensure that patients with risk for exposure are protected [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Identifying risk factors for YEL-AVD is difficult because of the relatively low incidence. YEL-AVD does not appear to be caused by mutational changes in the virus [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/40,54,66\">",
"     40,54,66",
"    </a>",
"    ]. Rather, YEL-AVD is probably related to defects in host innate immunity; in affected individuals the early antiviral response appears to be impaired, allowing unchecked viral replication before activation of the adaptive immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acquired host factors appear to increase the risk of developing YEL-AVD after vaccination: advanced age and thymus disease and possibly female gender in younger persons [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/54,59,60,64,68\">",
"     54,59,60,64,68",
"    </a>",
"    ]. Thymus disease (eg, thymoma, myasthenia gravis) was present in 4 of the 23 reported cases; all underwent thymectomy 2 to 20 years before vaccination; [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/69\">",
"     69",
"    </a>",
"    ]. In addition, thymic involution increases with age and the associated immune suppression might contribute to the increase in risk of YEL-AVD in the elderly. There is some evidence that immune dysregulation associated with autoimmune diseases, such as systemic lupus erythematosus and Addison&rsquo;s disease, may also be a risk factor for YEL-AVD [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/17,66\">",
"     17,66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Clinical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated risks of illness and death due to yellow fever in an unvaccinated traveler to an endemic area are relatively high (1 in 1000 and 1 in 5000 per month, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/70\">",
"     70",
"    </a>",
"    ]. In the United States the risks of YEL-AND and YEL-AVD in travelers are estimated at 0.8 and 0.4 per 100,000 respectively, although the risk is higher in older adults. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Adverse effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Whom to vaccinate",
"    </span>",
"    &nbsp;&mdash;&nbsp;In accordance with the Centers for Disease Control and Prevention (CDC), the United States Advisory Committee on Immunization Practices (ACIP), and the World Health Organization (WHO), we recommend vaccination for travelers to yellow fever endemic areas of Africa and South America, and for residents of those areas [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/70-73\">",
"     70-73",
"    </a>",
"    ]. A biweekly \"Blue Sheet\" Summary of Health Information for International Travel published by the CDC provides updated information on countries officially reporting yellow fever [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/74\">",
"     74",
"    </a>",
"    ]. In addition, there is a free course available online which provides information and training about yellow fever to health care professionals who advise travelers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/75\">",
"     75",
"    </a>",
"    ]. The WHO is revising the geographic risk areas to create an evidence based analysis of the probability of exposure to yellow fever [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Due to the risk of serious adverse events (particularly in persons &gt;60 years of age), the benefit of immunization should be established based on careful review of the traveler's itinerary with respect to potential for exposure to yellow fever virus [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/17\">",
"     17",
"    </a>",
"    ]. Individuals traveling in rural areas of countries within yellow fever endemic zones should be immunized even in the absence of official yellow fever reports, since active transmission may be underrecognized.",
"   </p>",
"   <p>",
"    For individuals with allergy to egg proteins who clearly require immunization due to possible exposure to yellow fever virus, epidermal scratch and intradermal skin testing may be performed to help ascertain whether the vaccine can be given safely. Otherwise, desensitization may be used [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/76\">",
"     76",
"    </a>",
"    ]. Skin testing and desensitization are best performed by an experienced allergist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43097?source=see_link\">",
"     \"Allergic reactions to vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vaccination against yellow fever in endemic areas is performed as part of the Expanded Program of Immunization at nine months of age. In some African countries catch-up mass vaccination campaigns are undertaken based on assessments of geographic risk, as part of an initiative spearheaded by the WHO to increase vaccine coverage [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/77\">",
"     77",
"    </a>",
"    ]. Mass campaigns are also conducted in response to outbreaks in Africa and South America.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Certificates",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, the vaccine is distributed only through approved vaccinating centers, including travel clinics and some health departments. These designated centers are listed in a registry at the CDC travel website [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some countries in yellow fever endemic zones require an International Certificate of Vaccination as evidence of yellow fever immunization prior to entry; these are listed in the publications and websites of the CDC and WHO [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/71,74,78\">",
"     71,74,78",
"    </a>",
"    ]. In addition, some countries outside of yellow fever zones also require evidence of immunizations prior to entry for individuals with recent travel in endemic countries [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/55\">",
"     55",
"    </a>",
"    ]. The international certificate of immunization is valid for 10 years; a booster 0.5 mL dose is required every 10 years for the certificate to be reissued.",
"   </p>",
"   <p>",
"    Individuals with contraindications or precautions deemed to place the traveler at high risk of adverse events may receive a waiver letter from a physician for travel to areas where vaccination is an international travel requirement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Pregnancy and breast feeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy is a precaution for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/13/14550?source=see_link\">",
"     yellow fever vaccine",
"    </a>",
"    administration; in contrast, most other live vaccines are contraindicated in pregnancy. If travel is unavoidable and the risks for yellow fever virus exposure are felt to outweigh the vaccination risks, a pregnant woman should be vaccinated. If the risks for vaccination are felt to outweigh the risks for yellow fever virus exposure, pregnant women should be issued a medical waiver to fulfill health regulations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The safety of yellow fever vaccination during pregnancy has not been clearly established. Congenital infection appears to occur at a low rate (probably 1 to 2 percent) and has never been associated with fetal abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. Pregnant woman who inadvertently receive vaccination should be reassured; there is no rationale to interrupt the pregnancy.",
"   </p>",
"   <p>",
"    Administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/13/14550?source=see_link\">",
"     yellow fever vaccine",
"    </a>",
"    to breast-feeding women should be avoided except in situations where exposure to yellow fever viruses cannot be avoided or postponed. Yellow fever vaccine virus can be transmitted via breast-feeding; in one report, two infants acquired yellow fever vaccine virus via breast milk from mothers who had undergone yellow fever vaccination; the infant developed YEL-AND requiring hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/53,82\">",
"     53,82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Immunocompromised individuals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Yellow fever 17D vaccine should not be administered to immunocompromised individuals because of theoretical concerns about live attenuated virus vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contraindications include inherited immune deficiency, lymphoma, leukemia,",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    with low CD4 counts, immunosuppressive chemotherapy or radiotherapy, thymus disorders, DiGeorge's syndrome, and a history of thymectomy. Autoimmune disease may be a risk factor for YEL-AVD but is not a listed precaution in the vaccine label.",
"   </p>",
"   <p>",
"    Travelers with asymptomatic HIV infection may be immunized if potential exposure warrants; such patients should be advised of the possible risks of vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/79\">",
"     79",
"    </a>",
"    ]. In studies of HIV seropositive patients with CD4+ counts above",
"    <span class=\"nowrap\">",
"     200/microL,",
"    </span>",
"    all responded serologically and none had adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. Nevertheless, it is prudent to confirm development of neutralizing antibodies, since such individuals may have an impaired ability to respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/13/14550?source=see_link\">",
"     yellow fever vaccine",
"    </a>",
"    . Antibody testing can be arranged through state health department laboratories. Waiver letters can also be obtained for these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no specific yellow fever immune globulin product available. Immune globulin produced in the United States (where many military personnel have been vaccinated) frequently contains adequate titers of yellow fever neutralizing antibodies (typically 1:320). Passive immunization has been used off label to protect persons traveling to high-risk areas who have contraindications to vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/54\">",
"     54",
"    </a>",
"    ]. If exposure to yellow fever virus occurred at a defined time (eg, in the case of accidental exposure in the laboratory or to blood from an acutely ill patient), post exposure treatment with immune globulin (from United States donors) or interferon-alpha (preferably not longer-acting pegylated interferon) would be warranted. Treatment would be expected to be effective only within the first 24 hours after exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26535465\">",
"    <span class=\"h2\">",
"     Newer, potentially safer vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious adverse events (except acute hypersensitivity reactions) are caused by replicating virus. Therefore, efforts are underway to develop safer, inactivated vaccines. A whole-virion inactivated vaccine adsorbed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/16/27910?source=see_link\">",
"     aluminum hydroxide",
"    </a>",
"    adjuvant was protective in animal models and was shown to be well tolerated and immunogenic in a Phase I clinical trial [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15705/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Yellow fever is a mosquito-borne viral hemorrhagic fever with a high case fatality rate. Travelers to in tropical regions of South America and sub-Saharan Africa are at risk for acquisition of infection and require immunization. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mosquito-borne epidemics in Africa occur where human populations reside in high density and immunization coverage is low (so-called \"urban yellow fever\"). Fewer cases occur in South America than in Africa because transmission occurs principally from monkey to human via mosquito vectors, the vector density is relatively low, and vaccination coverage is relatively high (so-called \"jungle yellow fever\"). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Yellow fever is characterized by three stages: periods of infection, remission, and intoxication. The period of infection consists of viremia with nonspecific symptoms and signs including fever, malaise, headache, joint pain, nausea, and vomiting. This is followed by a period of remission with abatement of fever and symptoms lasting up to 48 hours. The subsequent period of intoxication is characterized by hepatic dysfunction, renal failure, coagulopathy, and shock. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis may be made by serology, by detection of viral genome by PCR in serum, by virus isolation or by histopathology and immunocytochemistry (port mortem samples only). Serologic diagnosis is best accomplished using an enzyme linked immunosorbent assay (ELISA) for IgM. The presence of IgM antibodies in a single sample provides a presumptive diagnosis; confirmation is made by a rise in titer between paired acute and convalescent samples or a fall between early and late convalescent samples. More specific neutralization tests may be performed but require a specialized laboratory. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of yellow fever consists of supportive care; there is no specific antiviral therapy available. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In accordance with the Centers for Disease Control and Prevention (CDC), the United States Advisory Committee on Immunization Practices (ACIP), and the World Health Organization (WHO), we recommend immunization for travelers to yellow fever endemic areas of Africa and South America, and for residents of those areas (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The vaccine may be administered to individuals over the age of nine months. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Prevention'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27\">",
"       'Whom to vaccinate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serious adverse reactions to the 17D vaccine include two syndromes,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/13/14550?source=see_link\">",
"       yellow fever vaccine",
"      </a>",
"      -associated neurotropic disease (YEL-AND) and yellow fever vaccine-associated viscerotropic disease (YEL-AVD). In the United States the risks of YEL-AND and YEL-AVD in civilian travelers are estimated at 0.8 and 0.4 per 100,000 respectively, although the risk is higher in older adults, persons with immune dysregulation, and possibly young females. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some countries in yellow fever endemic zones require an International Certificate of Vaccination as evidence of yellow fever immunization prior to entry. In addition, some countries outside of yellow fever zones also require evidence of immunizations prior to entry for individuals with recent travel in endemic countries. The international certificate of immunization is valid for 10 years; a booster 0.5 mL dose is required every 10 years for the certificate to be reissued. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Certificates'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/1\">",
"      Mutebi JP, Wang H, Li L, et al. Phylogenetic and evolutionary relationships among yellow fever virus isolates in Africa. J Virol 2001; 75:6999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/2\">",
"      Vasconcelos PF, Bryant JE, da Rosa TP, et al. Genetic divergence and dispersal of yellow fever virus, Brazil. Emerg Infect Dis 2004; 10:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/3\">",
"      Dennis LH, Reisberg BE, Crosbie J, et al. The original haemorrhagic fever: yellow fever. Br J Haematol 1969; 17:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/4\">",
"      Tigertt WD, Berge TO, Gochenour WS, et al. Experimental yellow fever. Trans N Y Acad Sci 1960; 22:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/5\">",
"      Monath TP, Brinker KR, Chandler FW, et al. Pathophysiologic correlations in a rhesus monkey model of yellow fever with special observations on the acute necrosis of B cell areas of lymphoid tissues. Am J Trop Med Hyg 1981; 30:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/6\">",
"      Monath TP, Barrett AD. Pathogenesis and pathophysiology of yellow fever. Adv Virus Res 2003; 60:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/7\">",
"      Quaresma JA, Barros VL, Fernandes ER, et al. Reconsideration of histopathology and ultrastructural aspects of the human liver in yellow fever. Acta Trop 2005; 94:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/8\">",
"      Bae HG, Drosten C, Emmerich P, et al. Analysis of two imported cases of yellow fever infection from Ivory Coast and The Gambia to Germany and Belgium. J Clin Virol 2005; 33:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/9\">",
"      Quaresma JA, Barros VL, Pagliari C, et al. Revisiting the liver in human yellow fever: virus-induced apoptosis in hepatocytes associated with TGF-beta, TNF-alpha and NK cells activity. Virology 2006; 345:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/10\">",
"      Quaresma JA, Barros VL, Fernandes ER, et al. Immunohistochemical examination of the role of Fas ligand and lymphocytes in the pathogenesis of human liver yellow fever. Virus Res 2006; 116:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/11\">",
"      ter Meulen J, Sakho M, Koulemou K, et al. Activation of the cytokine network and unfavorable outcome in patients with yellow fever. J Infect Dis 2004; 190:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/12\">",
"      Tesh RB, Guzman H, da Rosa AP, et al. Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies. J Infect Dis 2001; 183:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/13\">",
"      Xiao SY, Zhang H, Guzman H, Tesh RB. Experimental yellow fever virus infection in the Golden hamster (Mesocricetus auratus). II. Pathology. J Infect Dis 2001; 183:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/14\">",
"      Meier KC, Gardner CL, Khoretonenko MV, et al. A mouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathog 2009; 5:e1000614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/15\">",
"      Monath TP. Yellow fever: Victor, Victoria? Conqueror, conquest? Epidemics and research in the last forty years and prospects for the future. Am J Trop Med Hyg 1991; 45:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/16\">",
"      Robertson SE, Hull BP, Tomori O, et al. Yellow fever: a decade of reemergence. JAMA 1996; 276:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/17\">",
"      Monath TP. Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines 2012; 11:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/18\">",
"      McFarland JM, Baddour LM, Nelson JE, et al. Imported yellow fever in a United States citizen. Clin Infect Dis 1997; 25:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/19\">",
"      Barros ML, Boecken G. Jungle yellow fever in the central Amazon. Lancet 1996; 348:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/20\">",
"      Centers for Disease Control and Prevention (CDC). Fatal yellow fever in a traveler returning from Venezuela, 1999. MMWR Morb Mortal Wkly Rep 2000; 49:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/21\">",
"      Colebunders R, Mariage JL, Coche JC, et al. A Belgian traveler who acquired yellow fever in the Gambia. Clin Infect Dis 2002; 35:e113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/22\">",
"      Centers for Disease Control and Prevention (CDC). Fatal yellow fever in a traveler returning from Amazonas, Brazil, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/23\">",
"      Outbreak news. Yellow fever, Paraguay. Wkly Epidemiol Rec 2008; 83:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/24\">",
"      Monath TP. Yellow fever: a medically neglected disease. Report on a seminar. Rev Infect Dis 1987; 9:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/25\">",
"      Barnett ED. Yellow fever: epidemiology and prevention. Clin Infect Dis 2007; 44:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/26\">",
"      Oudart JL, Rey M. [Proteinuria, proteinaemia, and serum transaminase activity in 23 confirmed cases of yellow fever]. Bull World Health Organ 1970; 42:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/27\">",
"      ELTON NW, ROMERO A, TREJOS A. Clinical pathology of yellow fever. Am J Clin Pathol 1955; 25:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/28\">",
"      Berry GP, Kitchen SF. Yellow fever accidentally contracted in the laboratory: A study of seven cases. Am J Trop Med Hyg 1931; 11:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/29\">",
"      Gibney KB, Edupuganti S, Panella AJ, et al. Detection of anti-yellow fever virus immunoglobulin m antibodies at 3-4 years following yellow fever vaccination. Am J Trop Med Hyg 2012; 87:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/30\">",
"      Lhuillier M, Sarthou JL, Cordellier R, et al. [Rural epidemic of yellow fever with interhuman transmission in the Ivory Coast in 1982]. Bull World Health Organ 1985; 63:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/31\">",
"      Monath TP, Ballinger ME, Miller BR, Salaun JJ. Detection of yellow fever viral RNA by nucleic acid hybridization and viral antigen by immunocytochemistry in fixed human liver. Am J Trop Med Hyg 1989; 40:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/32\">",
"      Vieira WT, Gayotto LC, de Lima CP, de Brito T. Histopathology of the human liver in yellow fever with special emphasis on the diagnostic role of the Councilman body. Histopathology 1983; 7:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/33\">",
"      De Brito T, Siqueira SA, Santos RT, et al. Human fatal yellow fever. Immunohistochemical detection of viral antigens in the liver, kidney and heart. Pathol Res Pract 1992; 188:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/34\">",
"      Monath TP. Treatment of yellow fever. Antiviral Res 2008; 78:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/35\">",
"      Gabrielsen B, Monath TP, Huggins JW, et al. Antiviral (RNA) activity of selected Amaryllidaceae isoquinoline constituents and synthesis of related substances. J Nat Prod 1992; 55:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/36\">",
"      Sbrana E, Xiao SY, Guzman H, et al. Efficacy of post-exposure treatment of yellow fever with ribavirin in a hamster model of the disease. Am J Trop Med Hyg 2004; 71:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/37\">",
"      Stephen EL, Sammons ML, Pannier WL, et al. Effect of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid complex on yellow fever in rhesus monkeys (Macaca mulatta). J Infect Dis 1977; 136:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/38\">",
"      Arroyo JI, Apperson SA, Cropp CB, et al. Effect of human gamma interferon on yellow fever virus infection. Am J Trop Med Hyg 1988; 38:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/39\">",
"      de Melo AB, da Silva Mda P, Magalh&atilde;es MC, et al. Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil. Am J Trop Med Hyg 2011; 85:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/40\">",
"      Galler R, Pugachev KV, Santos CL, et al. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology 2001; 290:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/41\">",
"      Mason RA, Tauraso NM, Spertzel RO, Ginn RK. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol 1973; 25:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/42\">",
"      Julander JG, Trent DW, Monath TP. Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. Vaccine 2011; 29:6008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/43\">",
"      Pulendran B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat Rev Immunol 2009; 9:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/44\">",
"      Querec TD, Akondy RS, Lee EK, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009; 10:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/45\">",
"      Gaucher D, Therrien R, Kettaf N, et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 2008; 205:3119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/46\">",
"      Scherer CA, Magness CL, Steiger KV, et al. Distinct gene expression profiles in peripheral blood mononuclear cells from patients infected with vaccinia virus, yellow fever 17D virus, or upper respiratory infections. Vaccine 2007; 25:6458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/47\">",
"      Querec T, Bennouna S, Alkan S, et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 2006; 203:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/48\">",
"      Miller JD, van der Most RG, Akondy RS, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 2008; 28:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/49\">",
"      Cao W, Manicassamy S, Tang H, et al. Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway. Nat Immunol 2008; 9:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/50\">",
"      Monath TP, Nichols R, Archambault WT, et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 2002; 66:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/51\">",
"      Belmusto-Worn VE, Sanchez JL, McCarthy K, et al. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am J Trop Med Hyg 2005; 72:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/52\">",
"      Centers for Disease Control and Prevention (CDC). Transfusion-related transmission of yellow fever vaccine virus--California, 2009. MMWR Morb Mortal Wkly Rep 2010; 59:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/53\">",
"      Kuhn S, Twele-Montecinos L, MacDonald J, et al. Case report: probable transmission of vaccine strain of yellow fever virus to an infant via breast milk. CMAJ 2011; 183:E243.",
"     </a>",
"    </li>",
"    <li>",
"     Monath TP, Gershman M, Staples JE, Barrett ADT. Yellow fever vaccine. In: Vaccines, 6th ed, Plotkin SA, Orenstein WA, Offit PA.  (Eds), Elsevier Saunders, 2012. p.870.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/55\">",
"      Centers for Disease Control and Prevention (CDC). Adverse events associated with 17D-derived yellow fever vaccination--United States, 2001-2002. MMWR Morb Mortal Wkly Rep 2002; 51:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/56\">",
"      Kitchener S. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX. Vaccine 2004; 22:2103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/57\">",
"      Kengsakul K, Sathirapongsasuti K, Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai 2002; 85:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/58\">",
"      McMahon AW, Eidex RB, Marfin AA, et al. Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases. Vaccine 2007; 25:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/59\">",
"      Lindsey NP, Schroeder BA, Miller ER, et al. Adverse event reports following yellow fever vaccination. Vaccine 2008; 26:6077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/60\">",
"      Khromava AY, Eidex RB, Weld LH, et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 2005; 23:3256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/61\">",
"      Martin M, Tsai TF, Cropp B, et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 2001; 358:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/62\">",
"      Vasconcelos PF, Luna EJ, Galler R, et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 2001; 358:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/63\">",
"      Chan RC, Penney DJ, Little D, et al. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 2001; 358:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/64\">",
"      Hayes EB. Acute viscerotropic disease following vaccination against yellow fever. Trans R Soc Trop Med Hyg 2007; 101:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/65\">",
"      Monath TP. Suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978), United States. Am J Trop Med Hyg 2010; 82:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/66\">",
"      Whittembury A, Ramirez G, Hern&aacute;ndez H, et al. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine 2009; 27:5974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/67\">",
"      Pulendran B, Miller J, Querec TD, et al. Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis 2008; 198:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/68\">",
"      Martin M, Weld LH, Tsai TF, et al. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis 2001; 7:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/69\">",
"      Barwick Eidex R, Yellow Fever Vaccine Safety Working Group. History of thymoma and yellow fever vaccination. Lancet 2004; 364:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/70\">",
"      Monath TP, Cetron MS. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis 2002; 34:1369.",
"     </a>",
"    </li>",
"    <li>",
"     CDC. Health information for international travel 2011-2012. DHHS, Atlanta, GA 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/72\">",
"      Cetron MS, Marfin AA, Julian KG, et al. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     www.who.org (Accessed on July 19, 2012).",
"    </li>",
"    <li>",
"     www.cdc.gov/travel (Accessed on July 18, 2012).",
"    </li>",
"    <li>",
"     file://www.cdc.gov/travel-training/ (Accessed on October 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/76\">",
"      Mosimann B, Stoll B, Francillon C, P&eacute;coud A. Yellow fever vaccine and egg allergy. J Allergy Clin Immunol 1995; 95:1064.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.who.int/csr/disease/yellowfev/brochure/en/index.html (Accessed on August 09, 2002).",
"    </li>",
"    <li>",
"     www.who.int/ith/ (Accessed on February 08, 2002).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/79\">",
"      Staples JE, Gershman M, Fischer M, Centers for Disease Control and Prevention (CDC). Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/80\">",
"      Nasidi A, Monath TP, Vandenberg J, et al. Yellow fever vaccination and pregnancy: a four-year prospective study. Trans R Soc Trop Med Hyg 1993; 87:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/81\">",
"      Tsai TF, Paul R, Lynberg MC, Letson GW. Congenital yellow fever virus infection after immunization in pregnancy. J Infect Dis 1993; 168:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/82\">",
"      Centers for Disease Control and Prevention (CDC). Transmission of yellow fever vaccine virus through breast-feeding - Brazil, 2009. MMWR Morb Mortal Wkly Rep 2010; 59:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/83\">",
"      Veit O, Niedrig M, Chapuis-Taillard C, et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis 2009; 48:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/84\">",
"      Tattevin P, Depatureaux AG, Chapplain JM, et al. Yellow fever vaccine is safe and effective in HIV-infected patients. AIDS 2004; 18:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15705/abstract/85\">",
"      Monath TP, Fowler E, Johnson CT, et al. An inactivated cell-culture vaccine against yellow fever. N Engl J Med 2011; 364:1326.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3032 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-996A9847C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_21_15705=[""].join("\n");
var outline_f15_21_15705=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VIROLOGY, PATHOGENESIS AND HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Transmission cycles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Period of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Period of remission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Period of intoxication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Hepatic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Renal dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Myocardial injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Central nervous system dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Rapid diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Virus isolation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Vaccine efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - YEL-AND",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - YEL-AVD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Clinical approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Whom to vaccinate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Certificates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Pregnancy and breast feeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Immunocompromised individuals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Immune globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26535465\">",
"      Newer, potentially safer vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43097?source=related_link\">",
"      Allergic reactions to vaccines",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_21_15706="Elective oophorectomy or ovarian conservation at the time of hysterectomy";
var content_f15_21_15706=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Elective oophorectomy or ovarian conservation at the time of hysterectomy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/21/15706/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/21/15706/contributors\">",
"     Susan D Reed, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/21/15706/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/21/15706/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/21/15706/contributors\">",
"     Howard T Sharp, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/21/15706/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/21/15706/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/21/15706/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H21231548\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hysterectomy (surgical removal of the uterus) is the second most common major surgical procedure (cesarean section is the most common) performed among United States women [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/1\">",
"     1",
"    </a>",
"    ]. Many women undergo oophorectomy at the time of hysterectomy. A 2005 United States nationwide study reported that unilateral or bilateral oophorectomy was performed in 68 percent of women at the time of abdominal hysterectomy, 60 percent at laparoscopic hysterectomy, and 26 percent at vaginal hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been common practice to counsel women who were in their mid-40s or older and were planning hysterectomy for benign indications to undergo concomitant bilateral salpingo-oophorectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/3\">",
"     3",
"    </a>",
"    ]. The rationale for this approach has been that oophorectomy greatly decreases the risk of ovarian cancer and the need for future ovarian surgery, and that there is little disadvantage, since women in this age range are close to or beyond menopause. This approach also assumed nearly universal treatment with postmenopausal hormone therapy. However, in recent decades, the debate over ovarian conservation versus elective oophorectomy at the time of hysterectomy has evolved with further understanding of potential long-term health risks and benefits of elective oophorectomy. In addition, clinical decision-making regarding hormone therapy has become more complex.",
"   </p>",
"   <p>",
"    For women with gynecologic malignancies, there are often clear indications for oophorectomy. In the setting of benign disease, however, the decision to retain or remove ovaries should be based upon the long-term health effects.",
"   </p>",
"   <p>",
"    An evidence-based approach to management of the ovaries at the time of hysterectomy for benign disease will be reviewed here. Techniques for oophorectomy, risk-reducing oophorectomy for women with a hereditary ovarian cancer syndrome, and general principles of menopause are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12393?source=see_link\">",
"     \"Oophorectomy and ovarian cystectomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34202?source=see_link\">",
"     \"Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44761?source=see_link\">",
"     \"Clinical manifestations and diagnosis of menopause\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12797502\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Elective salpingo-oophorectomy",
"      </strong>",
"      &ndash; Removal of the ovaries and fallopian tubes in a woman who has no known indication for this procedure (eg, ovarian pathology, hereditary ovarian cancer syndrome). Ovaries and tubes are typically removed, rather than the ovaries alone.",
"     </li>",
"     <li>",
"      <strong>",
"       Risk-reducing salpingo-oophorectomy",
"      </strong>",
"      &ndash; Removal of the ovaries and fallopian tubes in a woman with a hereditary ovarian cancer syndrome. Risk reduction requires removal of the tubes as well as the ovaries because some malignancies currently categorized as ovarian cancers may arise in the tubal epithelium. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34202?source=see_link\">",
"       \"Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The term",
"    <strong>",
"     prophylactic salpingo-oophorectomy",
"    </strong>",
"    has been used inconsistently, and so will not be used in this review, except when it was the term used in a particular study. It has been used variously to refer to salpingo-oophorectomy for the prevention of ovarian cancer in either women at an average risk or those with a hereditary ovarian cancer syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21231334\">",
"    <span class=\"h1\">",
"     SURGICAL EFFECTS ON OVARIAN FUNCTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12798786\">",
"    <span class=\"h2\">",
"     Surgical menopause",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ovary is an endocrine organ, with widespread physiologic effects during the postmenopausal, as well as the reproductive, years. &nbsp;",
"   </p>",
"   <p>",
"    In women who haven&rsquo;t previously undergone natural menopause, bilateral oophorectomy or remaining oophorectomy (removal of an ovary in a woman who has previously undergone unilateral oophorectomy) results in surgical menopause. The rapid change in the reproductive hormonal milieu and abrupt symptom onset that occurs in surgical menopause contrasts with the typical gradual waxing and waning in the hormonal profile and concomitant menopausal symptoms that occur in natural menopause.",
"   </p>",
"   <p>",
"    Surgical menopause results in an abrupt drop in estrogen levels, an abrupt rise in follicle stimulating hormone (FSH) level, and the complete cessation of ovarian hormone production, including androgens, estradiol, and progesterone [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/6-9\">",
"     6-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By contrast, the transition into natural menopause is characterized by variable estradiol and FSH levels, in association with unpredictable ovulatory and anovulatory cycles. The variability in hormone levels is most dramatic over a period of four years, and typically continues over an interval of up to 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Ultimately, estrogen levels remain low and FSH levels high, but there is no specific hormone level profile that unequivocally characterizes the onset of natural menopause. Intact postmenopausal ovaries continue to be hormonally active for many years beyond menopause, producing androgens including testosterone, androstenedione, and dehydroepiandrosterone (DHEA), as well as very small amounts of estradiol and estrone [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/12\">",
"     12",
"    </a>",
"    ]. Although estrogen secretion by the postmenopausal ovary eventually ceases, ovarian secretion of small amounts of testosterone and the androgen precursor, DHEA, may continue into the eighth decade of life [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/8,12\">",
"     8,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Extraovarian sources of sex steroids throughout life include the adrenal glands and widespread target tissues, including fat, where aromatization of androgens into estrogen occurs. The extent to which extraovarian sex steroid hormone synthesis differs between women who have experienced natural versus surgical menopause has been debated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/8,9\">",
"     8,9",
"    </a>",
"    ], but it appears that total androgen levels remain lower after surgical menopause than after natural menopause [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12798793\">",
"    <span class=\"h2\">",
"     Early menopause following hysterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hysterectomy appears to alter ovarian function over the long-term, even if the ovaries are conserved. This effect is incompletely understood, but is possibly due to impairment of the ovarian blood supply or other yet unknown mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. Observational studies have found that women who undergo hysterectomy develop menopausal symptoms and menopausal hormone profiles earlier than controls that did not have a hysterectomy. As an example, a prospective cohort study found that menopause (defined as follicle stimulating hormone &ge;40",
"    <span class=\"nowrap\">",
"     IU/L)",
"    </span>",
"    occurred 3.7 years earlier in premenopausal women who had a hysterectomy (both ovaries retained) compared with those who did not have a hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/16\">",
"     16",
"    </a>",
"    ]. And, among all women who underwent hysterectomy, those who had only one ovary conserved reached menopause 4.4 years earlier than those who had both ovaries conserved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24792659\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR OOPHORECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who undergo hysterectomy for benign indications may also have an indication for concurrent oophorectomy. Oophorectomy in this context is not elective. However, even in this circumstance, the risk-to-benefit balance of bilateral oophorectomy should be considered.",
"   </p>",
"   <p>",
"    Ovarian pathology is the usual indication for oophorectomy (eg, ovarian neoplasms). These indications are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12393?source=see_link&amp;anchor=H2#H2\">",
"     \"Oophorectomy and ovarian cystectomy\", section on 'Oophorectomy versus cystectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some women with extraovarian pathology may also benefit from oophorectomy, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Endometriosis",
"      </strong>",
"      &ndash; The risk of reoperation for endometriosis-related concerns appears to be lower if the ovaries are removed at the time of hysterectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14810?source=see_link&amp;anchor=H14#H14\">",
"       \"Overview of the treatment of endometriosis\", section on 'Indications for surgery'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Tuboovarian abscess",
"      </strong>",
"      &ndash; In women requiring surgical management of tuboovarian abscess, the risk of reoperation is higher if one or both ovaries are conserved [",
"      <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43560?source=see_link&amp;anchor=H26297696#H26297696\">",
"       \"Management and complications of tuboovarian abscess\", section on 'Surgery'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pelvic",
"       <span class=\"nowrap\">",
"        adhesions/pelvic",
"       </span>",
"       pain",
"      </strong>",
"      &ndash; The incidence of residual ovary syndrome, characterized by post-hysterectomy pelvic pain, is 0.9 to 3.4 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/19\">",
"       19",
"      </a>",
"      ]. Subsequent oophorectomy may be required to manage such symptoms. Preoperative pelvic pain and adhesions are risk factors for this syndrome. Thus, hysterectomy with bilateral salpingo-oophorectomy has been a common approach for such patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1235559\">",
"    <span class=\"h1\">",
"     STUDIES REGARDING ELECTIVE OOPHORECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The highest quality data regarding long-term health outcomes of elective oophorectomy compared with ovarian conservation at time of surgery are from two large prospective studies and a single retrospective cohort study discussed below; no randomized trial has investigated this issue:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Nurses&rsquo; Health Study was a prospective cohort study that included 29,380 women who had a hysterectomy for benign disease [",
"      <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/21\">",
"       21",
"      </a>",
"      ]. The average age at time of surgery was approximately 43 to 47 years and the average age at enrollment was 51 years; 94 percent were white; women were followed for 24 years.",
"     </li>",
"     <li>",
"      The Women&rsquo;s Health Initiative Observational Study was a prospective study that included 25,448 women who had a hysterectomy for benign disease [",
"      <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/22\">",
"       22",
"      </a>",
"      ]. Women in this study were initially invited to participate in the Women&rsquo;s Health Initiative randomized trial that evaluated postmenopausal hormone therapy, but were either found ineligible or declined to participate in the trial. The majority of women were 49 years or younger at the time of hysterectomy and the average age at enrollment was 63 years; 82 percent were white; women were followed for an average of only eight years.",
"     </li>",
"     <li>",
"      The Mayo Clinic Cohort Study of Oophorectomy and Aging was a retrospective population-based cohort study of 2365 women in Olmstead County, Minnesota who underwent unilateral or bilateral oophorectomy for benign disease; almost all women were white [",
"      <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/23\">",
"       23",
"      </a>",
"      ]. For some analyses, women from the cohort were compared with controls who had not had an oophorectomy and were identified via random digit telephone dialing [",
"      <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/24\">",
"       24",
"      </a>",
"      ]. The median age at time of surgery was 44 years among premenopausal women who had a bilateral oophorectomy and 62 years among postmenopausal women. Women who had a bilateral oophorectomy were followed for an average of 25 years; 95 percent had the oophorectomy at the time of hysterectomy. Although this study was retrospective, it includes prospective data from centralized medical records regarding the surgical, pharmacy, and outcome data for all participants. Thus, recall bias was limited and there was access to long-term follow-up data.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Findings from these studies, as well as from other relevant studies, are reviewed in the sections that follow. Data from the Women&rsquo;s Health Initiative conflict with data from the Nurses&rsquo; Health Study and the Mayo Clinic Cohort Study regarding many outcomes, including risk of all-cause mortality, cardiovascular disease and osteoporotic fractures. We regard the Nurses&rsquo; Health Study as having the best available data, based upon several methodologic limitations of the Women&rsquo;s Health Initiative Observational Study. Both the Nurses&rsquo; Health Study and the Mayo Clinic Cohort Study had long follow-up periods (24 to 30 years), adequate to assess outcomes that are more common for women over age 60 years: cardiovascular disease and stroke, dementia, osteoporosis, breast cancer, ovarian cancer and all-cause mortality, and shorter gaps between oophorectomy and enrollment. In contrast, women in the Women&rsquo;s Health Initiative were followed for only a mean of 8 years with an average gap of 14 years from oophorectomy to enrollment. The average age at enrollment in the Women&rsquo;s Health Initiative Observational Study was 63 years. Thus, women who had outcomes of interest (cardiovascular disease and stroke, dementia, osteoporosis, breast cancer, ovarian cancer and all-cause mortality) that occurred during the interval from hysterectomy to enrollment were not included, introducing a significant survivor bias to the analysis. Finally, the Women&rsquo;s Health Initiative Observational Study reported that bilateral salpingo-oophorectomy did not have significant adverse effects on all-cause mortality, coronary heart disease, hip fracture, or cancer, but the study has insufficient statistical power to detect differences for these outcomes. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24792980\">",
"    <span class=\"h1\">",
"     BENEFITS OF ELECTIVE OOPHORECTOMY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24793011\">",
"    <span class=\"h2\">",
"     Ovarian cancer risk reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral salpingo-oophorectomy (BSO) reduces, but does not eliminate, the risk of developing ovarian cancer. Ovarian-like cancers of the peritoneum, known as peritoneal cancer, may develop after oophorectomy. Oophorectomy performed for ovarian cancer risk reduction should include removal of the fallopian tubes since occult primary fallopian tubal cancers have been reported in women undergoing risk-reducing BSO. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=see_link&amp;anchor=H7#H7\">",
"     \"Epithelial ovarian cancer: Pathology\", section on 'Peritoneal carcinoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link&amp;anchor=H586132#H586132\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\", section on 'Incidental operative finding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    BSO is an important risk reduction strategy for women who are at high risk of ovarian cancer. The lifetime risk of ovarian cancer in the general population is 1.4 percent compared with 13 to 46 percent in women with BRCA1 or BRCA2 gene mutations (",
"    <a class=\"graphic graphic_table graphicRef68548 \" href=\"UTD.htm?7/40/7821\">",
"     table 1",
"    </a>",
"    ) and 3 to 14 percent in those with Lynch syndrome (hereditary nonpolyposis colorectal cancer syndrome) (",
"    <a class=\"graphic graphic_figure graphicRef57830 \" href=\"UTD.htm?2/0/2049\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/25\">",
"     25",
"    </a>",
"    ]. Salpingo-oophorectomy in these women is considered risk-reducing and not elective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18233?source=see_link\">",
"     \"Endometrial and ovarian cancer screening and prevention in women with Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link&amp;anchor=H13#H13\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\", section on 'Ovarian cancer'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34202?source=see_link\">",
"     \"Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The degree of ovarian cancer risk reduction from hysterectomy with BSO in the general population was illustrated in prospective data from the Nurses' Health Study (see",
"    <a class=\"local\" href=\"#H1235559\">",
"     'Studies regarding elective oophorectomy'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/21\">",
"     21",
"    </a>",
"    ]. The analyses were adjusted for family history of ovarian cancer and duration of oral contraceptive use. Women who underwent oophorectomy had significant reductions in ovarian cancer incidence (2 versus 42 cases per 100,000 person-years; HR 0.04, 95% CI 0.01-0.09) and ovarian cancer mortality (1 versus 14 deaths per 100,000 person-years; HR 0.06, 95% CI 0.02-0.21) compared with women who conserved their ovaries; this risk reduction was similar regardless of age at hysterectomy. Based upon these data, the number needed to treat to avoid one case of ovarian cancer was 220.",
"   </p>",
"   <p>",
"    Similar results were reported by the Women&rsquo;s Health Initiative Observational study, another large prospective cohort study, in which the number needed to treat to avoid one case of ovarian cancer was 323 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decision regarding BSO at time of hysterectomy is more difficult for women who have some risk factors for ovarian cancer (",
"    <a class=\"graphic graphic_table graphicRef59585 \" href=\"UTD.htm?11/59/12221\">",
"     table 2",
"    </a>",
"    ), but who do not have, or have not been tested for, a hereditary ovarian cancer syndrome. Women for whom a familial cancer syndrome is suspected should be offered genetic counseling and testing (",
"    <a class=\"graphic graphic_table graphicRef65717 \" href=\"UTD.htm?41/49/42779\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef59832 \" href=\"UTD.htm?3/37/3675\">",
"     table 4",
"    </a>",
"    ). Counseling of patients who have some of the known risk factors for ovarian cancer, but who do not meet criteria for a high risk of ovarian cancer, must be individualized and should include review of all advantages and disadvantages of the procedure. This is an area of uncertainty in which further research is needed to guide the practice. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/60/5064?source=see_link\">",
"     \"Genetic risk assessment for individuals at risk for hereditary breast and ovarian cancer syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8214654\">",
"    <span class=\"h3\">",
"     Alternatives to BSO for ovarian cancer risk reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical procedures other than BSO may reduce the risk of ovarian cancer, without resulting in surgical menopause.",
"   </p>",
"   <p>",
"    Procedures that interrupt or remove the fallopian tubes appear to reduce the risk of ovarian cancer, but not to the same extent as BSO. Hysterectomy alone was associated with a 34 percent reduction in the risk of ovarian cancer in a meta-analysis of 12 case-control studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/26\">",
"     26",
"    </a>",
"    ]. Tubal ligation was found to be associated with a 34 percent reduction in ovarian cancer risk in meta-analysis of case-control studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/27\">",
"     27",
"    </a>",
"    ]. Bilateral salpingectomy alone without oophorectomy has also been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25978?source=see_link&amp;anchor=H6092319#H6092319\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors\", section on 'Hysterectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potential mechanisms for the protective effect of these procedures include: (1) eliminating lesions that may have originated in the fallopian tubes; (2) limiting the potential for upward migration of carcinogens through the vagina, cervix, and fallopian tubes into the peritoneal cavity; and (3) providing a cancer screening effect [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unilateral oophorectomy has not been proven to reduce the risk of ovarian cancer. Although this observation is counterintuitive, available data have not consistently demonstrated that removing half of the tissue at risk results in half the risk of ovarian cancer. A multicenter case-control study of 1031 women with ovarian cancer who were compared with women who did not undergo pelvic surgery found no significant decrease in ovarian cancer risk over a period of seven years in those who underwent unilateral oophorectomy either with hysterectomy (1.4 versus 2.6 percent) or without hysterectomy (1.0 versus 1.6 percent) compared with no pelvic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/31\">",
"     31",
"    </a>",
"    ]. In contrast, a case-control study of 129 women with ovarian cancer found a significantly decreased rate of ovarian cancer over a period of 16 years in women who had undergone unilateral oophorectomy (2.9 versus 13.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/32\">",
"     32",
"    </a>",
"    ]. Further study of this issue is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8214361\">",
"    <span class=\"h2\">",
"     Breast cancer risk reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oophorectomy appears to reduce the risk of breast cancer in women who are 45 years old or younger at time of surgery. The reduced risk of breast cancer is likely due to reduced exposure to estrogen from the premenopausal ovary. This effect is also seen in women at high risk of breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34202?source=see_link&amp;anchor=H6#H6\">",
"     \"Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer\", section on 'Breast cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Nurses' Health Study was a large prospective study that reported a reduction in breast cancer risk in young women who underwent oophorectomy; analyses were adjusted for family history of breast cancer and use of estrogen therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1235559\">",
"     'Studies regarding elective oophorectomy'",
"    </a>",
"    above.) A significant reduction in breast cancer incidence was found",
"    <strong>",
"     only",
"    </strong>",
"    in women who underwent oophorectomy at less than 45 years old (222 versus 315 cases per 100,000 person-years; HR 0.6, 95% CI 0.5-0.7) and not in other women. No significant difference in breast cancer mortality was found in any age group.",
"   </p>",
"   <p>",
"    In contrast, the Women&rsquo;s Health Initiative Observational study found",
"    <strong>",
"     no",
"    </strong>",
"    significant reduction in breast cancer risk in women who underwent oophorectomy compared with those who did not undergo oophorectomy; these findings can be explained by significant limitations in the study design [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1235559\">",
"     'Studies regarding elective oophorectomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24793003\">",
"    <span class=\"h2\">",
"     Avoiding the need for subsequent oophorectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reoperation for ovarian pathology, termed residual ovary syndrome, occurred in 3 to 4 percent of women who retained one or both ovaries after hysterectomy, based upon two case series performed between 1970 and 1990 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/19,33\">",
"     19,33",
"    </a>",
"    ]. The majority of these surgeries were performed within five years of the hysterectomy for the indication of pelvic pain or a pelvic mass. In one series of 2561 hysterectomies, among 73 women with residual ovary syndrome, histologic examination revealed functional cysts in 51 percent, benign neoplasms in 43 percent, and ovarian carcinoma in 12 percent of cases (some patients had more than one diagnosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/19\">",
"     19",
"    </a>",
"    ]. The other series included 1265 women and found that the frequency of residual ovary syndrome was twice as high in women who had one ovary preserved, rather than both (7.6 versus 3.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/33\">",
"     33",
"    </a>",
"    ]. In addition, residual ovary syndrome was more common in women who underwent hysterectomy at a young age, possibly because of the longer period of post-procedure ovarian function with a greater opportunity for functional ovarian pathology.",
"   </p>",
"   <p>",
"    Some data suggest that the reoperation rate is higher in women who undergo abdominal or laparoscopic hysterectomy compared with a vaginal route [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/34\">",
"     34",
"    </a>",
"    ]. The reason for such a difference is uncertain, but it could be that vaginal hysterectomy is typically not performed when ovarian pathology in one or both ovaries is suspected.",
"   </p>",
"   <p>",
"    In women who require oophorectomy subsequent to hysterectomy, laparoscopic techniques have reduced the surgical morbidity of such procedures. However, surgical adhesions from prior hysterectomy may make a laparoscopic approach more difficult. One small study reported that 32 of 35 women with a prior hysterectomy were able to have a successful laparoscopic oophorectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/20\">",
"     20",
"    </a>",
"    ]. Thus, minimally invasive surgery will provide a solution for most women who develop ovarian pathology following hysterectomy. Therefore, the possible need for subsequent surgery does not appear to justify the deleterious long-term consequences of BSO for most women undergoing hysterectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24792988\">",
"    <span class=\"h1\">",
"     RISKS OF ELECTIVE OOPHORECTOMY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24792996\">",
"    <span class=\"h2\">",
"     Added surgical risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Operative complications are uncommon in women undergoing elective bilateral salpingo-oophorectomy (BSO) at the time of hysterectomy. The risk of such complications is increased if adhesions or other intraabdominal pathology are present.",
"   </p>",
"   <p>",
"    The impact of BSO on surgical morbidity is controversial. This may depend somewhat upon surgical route. For hysterectomy performed via laparotomy or laparoscopy, BSO does not appreciably increase the complexity of the procedure. In contrast, when BSO is combined with vaginal hysterectomy, the procedure is potentially more difficult. The degree of difficulty depends upon the extent of descensus of the ovaries and the extent to which the ovaries can be brought into the narrow surgical field. This is consistent with the findings of a study of over two million women in the United States who underwent hysterectomy for benign indications from 1998 to 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/35\">",
"     35",
"    </a>",
"    ]. There was an increase in complications when BSO was performed in women undergoing vaginal hysterectomy (OR 1.12; 95% CI 1.08-1.17), but not for those who had an abdominal (OR 0.91; 95% CI 0.89-0.94) or laparoscopic hysterectomy (OR 0.89; 95% CI 0.83-0.94). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/46/32490?source=see_link&amp;anchor=H20#H20\">",
"     \"Abdominal hysterectomy\", section on 'Adnexal conservation or removal'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35401?source=see_link&amp;anchor=H9#H9\">",
"     \"Vaginal hysterectomy\", section on 'Salpingo-oophorectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, an increase in morbidity with BSO was found in another study of over nine million women who had a hysterectomy performed between 1979 and 2004 identified via the United States National Hospital Discharge Survey database. Most were abdominal hysterectomies (84 percent); individual rates of other surgical routes were not given [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/36\">",
"     36",
"    </a>",
"    ]. Although a study population with a predominantly abdominal surgical route is no longer representative of current practice, findings showed that hysterectomy with oophorectomy compared with hysterectomy alone had significantly increased risks of",
"    <span class=\"nowrap\">",
"     circulatory/bleeding",
"    </span>",
"    complications (1.4 versus 1.2 percent; OR 1.34, 95% CI 1.05&ndash;1.70), organ injury (1.3 versus 0.9 percent; OR 1.35, 95% CI 1.02&ndash;1.79), and gastrointestinal complications (1.7 versus 0.7 percent; OR 1.76, 95% CI 1.31&ndash;2.37) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The available data do not take into consideration whether the oophorectomy was elective or indicated. Some indications for oophorectomy may contribute to surgical morbidity (eg, pelvic adhesions, large adnexal mass). Further study is needed to evaluate whether elective BSO impacts surgical morbidity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21231420\">",
"    <span class=\"h2\">",
"     Long-term health risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accumulating evidence indicates that surgical removal of the ovaries may have serious long-term health consequences [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/21-23,37-39\">",
"     21-23,37-39",
"    </a>",
"    ]. It appears that risks are greater for women who are younger at the time of oophorectomy and did not take estrogen therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/23,37-40\">",
"     23,37-40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H325404\">",
"    <span class=\"h3\">",
"     All-cause mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available evidence suggests that bilateral oophorectomy at younger age is associated with increased all-cause mortality, especially among women who do not take estrogen therapy. Questions remain regarding the potential mechanism of this effect, but evidence is suggestive that hypoestrogenism may be an important factor.",
"   </p>",
"   <p>",
"    The Nurses&rsquo; Health Study found that women who underwent bilateral oophorectomy had a significantly increased risk of death from all causes compared with those who conserved their ovaries (648 versus 527 per 100,000 person-years; HR 1.12; 95% CI, 1.03-1.21). (See",
"    <a class=\"local\" href=\"#H1235559\">",
"     'Studies regarding elective oophorectomy'",
"    </a>",
"    above.) This can also be expressed as one additional death over a period of 24 years for every 24 women who undergo bilateral oophorectomy at time of hysterectomy.",
"   </p>",
"   <p>",
"    The etiology of the increase in all-cause mortality in the Nurses&rsquo; Health Study is unknown, but younger women who did not take estrogen appeared to have the greatest risk (HR 1.40, 95% CI 1.01-1.96) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/21\">",
"     21",
"    </a>",
"    ]. Among all women, there were significant increases in deaths due to lung cancer (69 versus 54 per 100,000 person-years; HR 1.31, 95% CI 1.02&ndash;1.68) and there was an increased risk for coronary heart disease (75 versus 53 per 100,000 person-years; HR 1.28, 95% CI 1.00&ndash;1.64) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As in the Nurses&rsquo; Health Study, younger women in the Mayo Cohort Oophorectomy and Aging Study who underwent prophylactic BSO had an increased all-cause mortality risk (HR 1.67, 95% CI 1.16-2.40) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elective and indicated oophorectomies were analyzed separately in only one study, the Mayo Cohort Study of Oophorectomy and Aging [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1235559\">",
"     'Studies regarding elective oophorectomy'",
"    </a>",
"    above.) A significant increase in all-cause mortality compared with referent women without oophorectomy was found",
"    <strong>",
"     only",
"    </strong>",
"    in those in whom the oophorectomy was indicated due to a benign tumor or inflammation. The causes of death were not reported. The risk of death was significantly increased in women who underwent prophylactic oophorectomy compared with no oophorectomy",
"    <strong>",
"     only",
"    </strong>",
"    in those who were younger than age 45 years and did not use subsequent estrogen therapy (29 versus 26 percent). The study lacked sufficient statistical power to detect a difference in outcome in other women who underwent prophylactic oophorectomy. Further study of the distinction between indicated and elective oophorectomies is needed. (See",
"    <a class=\"local\" href=\"#H24792659\">",
"     'Indications for oophorectomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In contrast to findings from the Nurses&rsquo; Health Study and the Mayo Cohort Study of Oophorectomy and Aging, the Women&rsquo;s Health Initiative Observational Study found",
"    <strong>",
"     no",
"    </strong>",
"    increase in mortality in women who underwent hysterectomy with bilateral oophorectomy compared to ovarian conservation, overall (797 versus 791 per 100,000 person-years; HR 0.98, 95% CI 0.87-1.10) or for any age group subset [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/22\">",
"     22",
"    </a>",
"    ]. A discussion of study limitations can be found above. (See",
"    <a class=\"local\" href=\"#H1235559\">",
"     'Studies regarding elective oophorectomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21231434\">",
"    <span class=\"h3\">",
"     Cardiovascular disease and stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available evidence suggests that BSO at a younger age is associated with an increased risk of cardiovascular disease and stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/21,40,41\">",
"     21,40,41",
"    </a>",
"    ]. It is uncertain whether an increase in cardiovascular risk is the result of early menopause, or is associated specifically with surgical menopause. Some data suggest that estrogen therapy may mitigate adverse cardiovascular effects in this patient population [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/21,39\">",
"     21,39",
"    </a>",
"    ]. The relationship between postmenopausal hormone therapy and cardiovascular disease is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=see_link\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The association between cardiovascular disease and oophorectomy is supported by data from a meta-analysis and large observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/21,40-42\">",
"     21,40-42",
"    </a>",
"    ]. Women who undergo bilateral oophorectomy appear to be more likely than premenopausal women to develop cardiovascular disease, based upon a meta-analysis of 18 studies that found a significantly increased risk of cardiovascular disease in women who underwent bilateral oophorectomy compared with premenopausal women (RR 2.62, 95% CI, 2.05-3.35) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/41\">",
"     41",
"    </a>",
"    ]. In contrast, no significant difference was found between natural menopause and premenopause (RR 1.14, 95% CI 0.86-1.51). Surgical menopause was not directly compared with natural menopause. Early age at oophorectomy had a deleterious effect. The increase in cardiovascular risk was significantly higher in women who underwent bilateral oophorectomy before age 50 years compared with 50 years or older (RR 4.55, 95% CI 2.56-8.01).",
"   </p>",
"   <p>",
"    On the other hand, early natural menopause (&le;44 years old) has been associated with an increase in the risk of cardiovascular disease in two large epidemiologic studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. In one, this effect was limited to current smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/43\">",
"     43",
"    </a>",
"    ], while the second study only included women who never smoked [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28570?source=see_link&amp;anchor=H15#H15\">",
"     \"Determinants and management of cardiovascular risk in women\", section on 'Menopause'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Nurses&rsquo; Health Study found a significant increase in coronary heart disease among women who underwent oophorectomy (207 versus 163 per 100,000 person-years; HR 1.17, 95% CI 1.02&ndash;1.35) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/21\">",
"     21",
"    </a>",
"    ]. The findings can be expressed as one extra death from coronary heart disease for every 130 women having bilateral salpingo-oophorectomy. Subset analysis by age group found a significant increase in coronary heart disease",
"    <strong>",
"     only",
"    </strong>",
"    in women younger than 45 years at time of surgery (212 versus 147 per 100,000 person-years; HR 1.26, 95% CI 1.04&ndash;1.54).",
"   </p>",
"   <p>",
"    Similarly, among younger women in the Mayo Cohort Oophorectomy and Aging Study, women who underwent BSO and were",
"    <strong>",
"     not",
"    </strong>",
"    treated with estrogen from the time of BSO through age 45 years had an increased cardiovascular mortality risk (HR 1.84, 95% CI 1.27-2.68), while those who were treated with estrogen therapy were not found to have a significantly increased risk (HR 0.65, 95% CI 0.30-1.41), although this analysis had insufficient statistical power [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, the Women&rsquo;s Health Initiative Observational study found no significant association between oophorectomy and coronary heart disease (380 versus 353 per 100,000 person-years; HR 1.00, 0.85-1.18); however, methodologic issues limit confidence in this finding [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/22\">",
"     22",
"    </a>",
"    ]. A discussion of study limitations can be found above. (See",
"    <a class=\"local\" href=\"#H1235559\">",
"     'Studies regarding elective oophorectomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Neither study found a significant association overall between oophorectomy and stroke. A significant association between oophorectomy and stroke was found only in a subset analysis in the Nurses&rsquo; Health Study of women who had oophorectomy performed before age 50 years and never used estrogen therapy (HR 2.19, 95% CI 1.16&ndash;4.14) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21231441\">",
"    <span class=\"h3\">",
"     Cognitive function and neurologic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oophorectomy prior to menopause appears to be associated with an increased risk of cognitive impairment or dementia, as well as parkinsonism. Estrogen replacement may be neuroprotective in these women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/63/41975?source=see_link&amp;anchor=H14#H14\">",
"     \"Estrogen and cognitive function\", section on 'Timing of exposure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link&amp;anchor=H438948986#H438948986\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\", section on 'Cognitive function and dementia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This was illustrated in the Mayo Clinic Cohort Study of Oophorectomy and Aging [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Among women who underwent bilateral oophorectomy before menopause compared with those who did not undergo oophorectomy, a significant increase in the risk of cognitive impairment or dementia was restricted to those who were younger than 48 years old at time of surgery and who did not take estrogen therapy from time of surgery through age 50 years (HR 1.89, 95% CI 1.27&ndash;2.83). &nbsp;",
"   </p>",
"   <p>",
"    Small observational studies have shown a significant decrease in specific cognitive functions after bilateral oophorectomy, including verbal fluency, verbal memory, procedural learning, and some other executive functions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/37,47\">",
"     37,47",
"    </a>",
"    ]. Neurocognitive performance was worse when oophorectomy occurred at younger ages and worse with a greater decline in estradiol levels, but it was better when hormone therapy was initiated after oophorectomy. The extent to which observed improvements in neurocognitive performance with estrogen therapy might be attributable to improvements in sleep and relief of hot flashes versus direct effects on the brain has been debated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the Mayo Clinic Cohort Study of Oophorectomy and Aging, women who underwent bilateral oophorectomy before the onset of menopause had an increased risk of parkinsonism compared with no oophorectomy (2.6 versus 1.2 percent), and the risk increased with younger age at oophorectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/46,48\">",
"     46,48",
"    </a>",
"    ]. An increase in the risk of Parkinson&rsquo;s disease was also found, but did not reach statistical significance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21231462\">",
"    <span class=\"h3\">",
"     Depression and anxiety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some data suggest that early bilateral oophorectomy at the time of hysterectomy is associated with an increased risk of developing depression or anxiety [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/37,49,50\">",
"     37,49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Mayo Clinic Cohort Study of Oophorectomy and Aging reported that women who had bilateral oophorectomy compared with those who did not had a significant increase in the onset of symptoms of depression (as diagnosed by a physician, 11 versus 7 percent) or anxiety (7 versus 3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/37\">",
"     37",
"    </a>",
"    ]. The median time from oophorectomy to the onset of symptoms of depression or anxiety was approximately 14 years, but differences in the rates of occurrence of anxiety and depression were observed within three years following hysterectomy, and persisted throughout more than 30 years of follow-up.",
"   </p>",
"   <p>",
"    The Study of Women Across the Nation, a prospective cohort study of over 3000 women from diverse ethnic backgrounds, compared risk of depression and anxiety among women who had hysterectomy with ovarian conservation (n = 76) versus women who had hysterectomy with bilateral oophorectomy (n = 101). For all women, depressive and anxiety symptoms decreased in the years after final menstrual period or surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from shorter-term studies have been inconsistent regarding the effect of bilateral oophorectomy on psychological well-being [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H326764\">",
"    <span class=\"h3\">",
"     Sexual dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some but not all studies report negative sexual outcomes after oophorectomy.",
"   </p>",
"   <p>",
"    Adverse effects of bilateral oophorectomy can involve several different domains of sexual function, including libido, arousal, and orgasm [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/49\">",
"     49",
"    </a>",
"    ]. In a survey of European women with no known increased risk of cancer, those who underwent bilateral oophorectomy were twice as likely to have hypoactive sexual desire symptoms compared with women who were premenopausal or had gone through natural menopause [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Greater impairment of sexual function may be associated with surgical versus natural menopause since only surgical menopause is associated with an abrupt decrease in androgen output. In a cross-sectional study of over 30,000 women, surgical, but not natural, menopause was associated with orgasm problems and the decrease in arousal was greater in women after surgical menopause [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/54\">",
"     54",
"    </a>",
"    ]. Similarly, in one retrospective study of women following hysterectomy, women who had bilateral oophorectomy reported significantly decreased sexual satisfaction postoperatively, despite estrogen treatment, compared to women who had their ovaries preserved [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/51\">",
"     51",
"    </a>",
"    ]. On the other hand, this result was not observed in a subsequent prospective study in which sexuality was unaltered postoperatively in women following hysterectomy with bilateral oophorectomy compared with hysterectomy only [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25258?source=see_link&amp;anchor=H8#H8\">",
"     \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\", section on 'Age and menopause'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several other studies have found that overall sexual function is unaltered after oophorectomy, or that alterations were explained by preoperative sexual function, indications for surgery, severity of symptoms, and personality traits, rather than by the oophorectomy itself [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/3,56-58\">",
"     3,56-58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H326484\">",
"    <span class=\"h3\">",
"     Osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Menopause is a known risk factor for osteoporosis. Among women in the Mayo Clinic Cohort of Oophorectomy and Aging who were postmenopausal at the time of surgery, there was a significant increase in the risk of any osteoporotic fracture (moderate trauma fractures of the hip, spine, or distal forearm) as compared to expected rates (standardized incidence ratio [SIR] 1.54; 95% CI, 1.29&ndash;1.82), but almost as large an increase in fractures at other sites (SIR 1.35; 95% CI, 1.13&ndash;1.59) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/59\">",
"     59",
"    </a>",
"    ]. Likewise, women who were premenopausal at the time of surgery had an increased risk of distal forearm (SIR 1.4, 95% CI 1.0-2.0) and vertebral fractures (SIR 1.9, 95% CI 1.3-2.8), but not hip fracture (SRI 1.1, 95% CI 0.6-1.9) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, oophorectomy at time of hysterectomy was not found to be associated with hip fracture in either the Nurses&rsquo; Health Study or the Women&rsquo;s Health Initiative Observational Study [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1235559\">",
"     'Studies regarding elective oophorectomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8214913\">",
"    <span class=\"h1\">",
"     CLINICAL DECISION-MAKING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision regarding elective oophorectomy at time of hysterectomy for benign indications is complex. The approach to such decisions must include comprehensive counseling regarding risks and benefits and shared decision-making between the clinician and patient. &nbsp;",
"   </p>",
"   <p>",
"    The first step is to determine whether the choice regarding oophorectomy is truly elective (see",
"    <a class=\"local\" href=\"#H24792659\">",
"     'Indications for oophorectomy'",
"    </a>",
"    above). All women planning hysterectomy should be assessed for risk factors for ovarian and breast cancer. In addition, an appropriate evaluation for extrauterine pelvic pathology should be performed. Strategies for cancer risk reduction in women at high risk of ovarian cancer due to hereditary ovarian and breast cancer syndromes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34202?source=see_link&amp;anchor=H2#H2\">",
"     \"Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer\", section on 'Cancer risk reduction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17418?source=see_link\">",
"     \"Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bilateral oophorectomy is associated with a small absolute cancer risk reduction for women who are at an average risk of ovarian or breast cancer. Ovarian cancer is not a common disease and hysterectomy itself provides a small preventive effect. Some data suggest an association between oophorectomy and decreased risk of breast cancer in women who are younger than 45 years, but no decrease in breast cancer mortality has been found. (See",
"    <a class=\"local\" href=\"#H24793011\">",
"     'Ovarian cancer risk reduction'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H8214361\">",
"     'Breast cancer risk reduction'",
"    </a>",
"    above.).",
"   </p>",
"   <p>",
"    There are conflicting data on long-term health effects of elective oophorectomy beyond ovarian and breast cancer risk reduction. The best available data are from observational studies, some of which conflict with each other. Given the current evidence, elective oophorectomy may be associated with an increase in long-term risks of all-cause mortality and cardiovascular disease, particularly in women who are younger than 45 to 54 years at the time of surgery (see",
"    <a class=\"local\" href=\"#H325404\">",
"     'All-cause mortality'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H21231434\">",
"     'Cardiovascular disease and stroke'",
"    </a>",
"    above). Cognitive impairment, parkinsonism, psychiatric symptoms, sexual dysfunction, and osteoporosis are additional risks. (See",
"    <a class=\"local\" href=\"#H21231441\">",
"     'Cognitive function and neurologic disease'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H21231462\">",
"     'Depression and anxiety'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H326764\">",
"     'Sexual dysfunction'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H326484\">",
"     'Osteoporosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In the short-term, premenopausal women who undergo bilateral oophorectomy will experience the abrupt onset of menopause and will typically have bothersome menopausal symptoms (eg, hot flashes, sleep disturbance, and mood changes). These symptoms may be treated with postmenopausal estrogen therapy; significant risks of therapy have not been demonstrated in premenopausal women. Withholding estrogen therapy from young women who experience premature or early menopause due to oophorectomy, however, may, on the other hand, pose significant risks, based on the evidence presented here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37880?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of spontaneous primary ovarian insufficiency (premature ovarian failure)\", section on 'Duration of estrogen therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For women who have already experienced natural menopause, elective bilateral oophorectomy may be health neutral. Although, a decision analysis based upon a comprehensive review of observational data concluded that ovarian conservation at time of benign hysterectomy until age 65 years benefits long-term survival, and that the risks and benefits of elective oophorectomy approximate each other after age 65 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American College of Obstetrics and Gynecology (ACOG) advises strong consideration of ovarian conservation at time of hysterectomy in premenopausal women who are not at an increased genetic risk of ovarian cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/3\">",
"     3",
"    </a>",
"    ]. They advise consideration of oophorectomy at time of hysterectomy in women who are postmenopausal or who have a condition that may benefit from oophorectomy (eg, endometriosis, pelvic inflammatory disease, chronic pelvic pain). &nbsp;",
"   </p>",
"   <p>",
"    Given, these considerations and the available data, for most women who undergo hysterectomy for benign indications, in the absence of ovarian pathology or a familial cancer syndrome, we suggest ovarian conservation. Oophorectomy is reasonable for women who place a higher priority on ovarian cancer prevention than on other long-term health risks, particularly those who are 51 years old or older.",
"   </p>",
"   <p>",
"    The decision regarding salpingo-oophorectomy is more difficult for women who have some risk factors for ovarian cancer (",
"    <a class=\"graphic graphic_table graphicRef59585 \" href=\"UTD.htm?11/59/12221\">",
"     table 2",
"    </a>",
"    ), but who do not have a hereditary cancer syndrome. Ovarian cancer risk assessment tools have been proposed, but are not well validated. As an example, one case control study found a 4 percent lifetime increased risk of ovarian cancer in women with five or more of the following risk factors: Jewish ethnicity, less than one year of oral contraceptive use, nulliparity, no breastfeeding, no tubal ligation, painful periods or endometriosis, polycystic ovarian syndrome or obesity, and talc use [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/61\">",
"     61",
"    </a>",
"    ]. Counseling of such patients believed to be at intermediate risk of ovarian cancer must be individualized, and should include a full discussion of all of the advantages and disadvantages of the procedure. (See",
"    <a class=\"local\" href=\"#H24793011\">",
"     'Ovarian cancer risk reduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21231469\">",
"    <span class=\"h1\">",
"     ESTROGEN THERAPY AFTER OOPHORECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women experiencing premature or early menopause due to bilateral oophorectomy at the time of hysterectomy are different from women who reach menopause at the median age of 51 years, and data regarding the use of hormone therapy in naturally menopausal women should not be extrapolated to women who have surgical menopause at the time of hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. The risks of hormone therapy use by women with induced premature or early menopause may be greater due to the addition of progestin with estrogen therapy, but the benefits potentially greater, although controlled clinical trial data are lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/62\">",
"     62",
"    </a>",
"    ]. Typically, estrogen therapy for these women is recommended until the average age of natural menopause, in an effort to provide cardiac, cognitive, and bone protection, along with maintaining healthy sexual function [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Observational data consistently indicate that several of the serious long-term health consequences of bilateral oophorectomy can be ameliorated by taking estrogen therapy until at least age 50 to 51 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/23,39,45\">",
"     23,39,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37880?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of spontaneous primary ovarian insufficiency (premature ovarian failure)\", section on 'Duration of estrogen therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women who are treated with hormone therapy after hysterectomy may take estrogen therapy alone, since a progestogen for endometrial protection is not needed. Following bilateral oophorectomy, some clinicians treat women with androgen therapy for sexual dysfunction; other indications for androgens in this population are not well established and concern for increased risk of breast cancer and cardiovascular disease has been raised [",
"    <a class=\"abstract\" href=\"UTD.htm?15/21/15706/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34985?source=see_link&amp;anchor=H21#H21\">",
"     \"Sexual dysfunction in women: Management\", section on 'Androgens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21231476\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many women undergo oophorectomy at the time of hysterectomy. It has been common practice to counsel women who were planning hysterectomy for benign indications, and were in their mid-40s or older, to undergo concomitant bilateral oophorectomy. (See",
"      <a class=\"local\" href=\"#H21231548\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Elective oophorectomy refers to the removal of the ovaries in a woman who has no known indication for this procedure (eg, ovarian pathology, hereditary ovarian cancer syndrome). Risk-reducing oophorectomy refers to the removal of the ovaries in a woman at high risk of ovarian or breast cancer due to a known gene mutation. (See",
"      <a class=\"local\" href=\"#H12797502\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oophorectomy is associated with a reduction in the risk of ovarian cancer. Some data suggest that breast cancer risk is probably reduced in women who are premenopausal at time of surgery. (See",
"      <a class=\"local\" href=\"#H24793011\">",
"       'Ovarian cancer risk reduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8214361\">",
"       'Breast cancer risk reduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oophorectomy appears to increase long-term mortality and cardiovascular risk in women under the age of 45 years who do not take estrogen therapy. (See",
"      <a class=\"local\" href=\"#H21231420\">",
"       'Long-term health risks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oophorectomy, particularly before menopause, has potential deleterious effects on the risk for cognitive decline, parkinsonism, depression and anxiety, sexual dysfunction and osteoporotic fractures. (See",
"      <a class=\"local\" href=\"#H21231441\">",
"       'Cognitive function and neurologic disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21231462\">",
"       'Depression and anxiety'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H326764\">",
"       'Sexual dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most women who undergo hysterectomy for benign indications, in the absence of ovarian pathology or a familial cancer syndrome, we suggest ovarian conservation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Oophorectomy is reasonable, particularly for those who are 51 years of age or older, for women who place a higher priority on ovarian cancer prevention than on the potential risks of mortality and cardiovascular disease that have been suggested by some studies. (See",
"      <a class=\"local\" href=\"#H8214913\">",
"       'Clinical decision-making'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Counseling of women with risk factors for ovarian cancer (",
"      <a class=\"graphic graphic_table graphicRef59585 \" href=\"UTD.htm?11/59/12221\">",
"       table 2",
"      </a>",
"      ), but who do not have a hereditary cancer syndrome, must be individualized. (See",
"      <a class=\"local\" href=\"#H8214913\">",
"       'Clinical decision-making'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women who undergo oophorectomy inducing premature (before age 40 years) or early (before age 45 years) menopause are likely to benefit from estrogen therapy until they reach the average age of natural menopause. (See",
"      <a class=\"local\" href=\"#H21231469\">",
"       'Estrogen therapy after oophorectomy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37880?source=see_link\">",
"       \"Management of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/1\">",
"      Novetsky AP, Boyd LR, Curtin JP. Trends in bilateral oophorectomy at the time of hysterectomy for benign disease. Obstet Gynecol 2011; 118:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/2\">",
"      Jacoby VL, Autry A, Jacobson G, et al. Nationwide use of laparoscopic hysterectomy compared with abdominal and vaginal approaches. Obstet Gynecol 2009; 114:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/3\">",
"      ACOG. ACOG Practice Bulletin No. 89. Elective and risk-reducing salpingo-oophorectomy. Obstet Gynecol 2008; 111:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/4\">",
"      Berek JS, Chalas E, Edelson M, et al. Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. Obstet Gynecol 2010; 116:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/5\">",
"      Finch A, Metcalfe KA, Chiang JK, et al. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol Oncol 2011; 121:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/6\">",
"      Mercuro G, Zoncu S, Saiu F, et al. Menopause induced by oophorectomy reveals a role of ovarian estrogen on the maintenance of pressure homeostasis. Maturitas 2004; 47:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/7\">",
"      Lobo RA. Surgical menopause and cardiovascular risks. Menopause 2007; 14:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/8\">",
"      Labrie F, Martel C, Balser J. Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women: role of the ovary? Menopause 2011; 18:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/9\">",
"      Lasley BL, Crawford SL, Laughlin GA, et al. Circulating dehydroepiandrosterone sulfate levels in women who underwent bilateral salpingo-oophorectomy during the menopausal transition. Menopause 2011; 18:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/10\">",
"      Burger HG, Hale GE, Dennerstein L, Robertson DM. Cycle and hormone changes during perimenopause: the key role of ovarian function. Menopause 2008; 15:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/11\">",
"      Randolph JF Jr, Zheng H, Sowers MR, et al. Change in follicle-stimulating hormone and estradiol across the menopausal transition: effect of age at the final menstrual period. J Clin Endocrinol Metab 2011; 96:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/12\">",
"      Fogle RH, Stanczyk FZ, Zhang X, Paulson RJ. Ovarian androgen production in postmenopausal women. J Clin Endocrinol Metab 2007; 92:3040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/13\">",
"      Halmesm&auml;ki K, Hurskainen R, Tiitinen A, et al. A randomized controlled trial of hysterectomy or levonorgestrel-releasing intrauterine system in the treatment of menorrhagia-effect on FSH levels and menopausal symptoms. Hum Reprod 2004; 19:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/14\">",
"      Oldenhave A, Jaszmann LJ, Everaerd WT, Haspels AA. Hysterectomized women with ovarian conservation report more severe climacteric complaints than do normal climacteric women of similar age. Am J Obstet Gynecol 1993; 168:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/15\">",
"      Siddle N, Sarrel P, Whitehead M. The effect of hysterectomy on the age at ovarian failure: identification of a subgroup of women with premature loss of ovarian function and literature review. Fertil Steril 1987; 47:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/16\">",
"      Farquhar CM, Sadler L, Harvey SA, Stewart AW. The association of hysterectomy and menopause: a prospective cohort study. BJOG 2005; 112:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/17\">",
"      Catenacci M, Sastry S, Falcone T. Laparoscopic surgery for endometriosis. Clin Obstet Gynecol 2009; 52:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/18\">",
"      Wiesenfeld HC, Sweet RL. Progress in the management of tuboovarian abscesses. Clin Obstet Gynecol 1993; 36:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/19\">",
"      Dekel A, Efrat Z, Orvieto R, et al. The residual ovary syndrome: a 20-year experience. Eur J Obstet Gynecol Reprod Biol 1996; 68:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/20\">",
"      Salim R, Gray G, Chappatte OA. The feasibility and efficacy of laparoscopic oophorectomy in the management of pelvic pain after hysterectomy. J Obstet Gynaecol 2007; 27:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/21\">",
"      Parker WH, Broder MS, Chang E, et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol 2009; 113:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/22\">",
"      Jacoby VL, Grady D, Wactawski-Wende J, et al. Oophorectomy vs ovarian conservation with hysterectomy: cardiovascular disease, hip fracture, and cancer in the Women's Health Initiative Observational Study. Arch Intern Med 2011; 171:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/23\">",
"      Rocca WA, Grossardt BR, de Andrade M, et al. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 2006; 7:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/24\">",
"      Melton LJ 3rd, Crowson CS, Malkasian GD, O'Fallon WM. Fracture risk following bilateral oophorectomy. J Clin Epidemiol 1996; 49:1111.",
"     </a>",
"    </li>",
"    <li>",
"     file://seer.cancer.gov/statfacts/html/ovary.html (Accessed on April 24, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/26\">",
"      Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/27\">",
"      Cibula D, Widschwendter M, M&aacute;jek O, Dusek L. Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum Reprod Update 2011; 17:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/28\">",
"      Greene MH, Mai PL, Schwartz PE. Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers? Am J Obstet Gynecol 2011; 204:19.e1.",
"     </a>",
"    </li>",
"    <li>",
"     Salpingectomy recommended in British Columbia: file://www.ovcare.ca/news_practice%20changes.php (Accessed on April 27, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/30\">",
"      Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/31\">",
"      Chiaffarino F, Parazzini F, Decarli A, et al. Hysterectomy with or without unilateral oophorectomy and risk of ovarian cancer. Gynecol Oncol 2005; 97:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/32\">",
"      Beard CM, Hartmann LC, Atkinson EJ, et al. The epidemiology of ovarian cancer: a population-based study in Olmsted County, Minnesota, 1935-1991. Ann Epidemiol 2000; 10:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/33\">",
"      Pl&ouml;ckinger B, K&ouml;lbl H. Development of ovarian pathology after hysterectomy without oophorectomy. J Am Coll Surg 1994; 178:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/34\">",
"      Holub Z, Jandourek M, Jabor A, et al. Does hysterectomy without salpingo-oophorectomy influence the reoperation rate for adnexal pathology? A retrospective study. Clin Exp Obstet Gynecol 2000; 27:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/35\">",
"      Asante A, Whiteman MK, Kulkarni A, et al. Elective oophorectomy in the United States: trends and in-hospital complications, 1998-2006. Obstet Gynecol 2010; 116:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/36\">",
"      Lowder JL, Oliphant SS, Ghetti C, et al. Prophylactic bilateral oophorectomy or removal of remaining ovary at the time of hysterectomy in the United States, 1979-2004. Am J Obstet Gynecol 2010; 202:538.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/37\">",
"      Shuster LT, Gostout BS, Grossardt BR, Rocca WA. Prophylactic oophorectomy in premenopausal women and long-term health. Menopause Int 2008; 14:111.",
"     </a>",
"    </li>",
"    <li>",
"     Shuster, LT, Grossardt, BR, Gostout, BS, Rocca, WA. Prophylactic bilateral oophorectomy jeopardizes long-term health. Menopausal Medicine 2010; 18:S1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/39\">",
"      Rivera CM, Grossardt BR, Rhodes DJ, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 2009; 16:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/40\">",
"      L&oslash;kkegaard E, Jovanovic Z, Heitmann BL, et al. The association between early menopause and risk of ischaemic heart disease: influence of Hormone Therapy. Maturitas 2006; 53:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/41\">",
"      Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006; 13:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/42\">",
"      Ingelsson E, Lundholm C, Johansson AL, Altman D. Hysterectomy and risk of cardiovascular disease: a population-based cohort study. Eur Heart J 2011; 32:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/43\">",
"      Hu FB, Grodstein F, Hennekens CH, et al. Age at natural menopause and risk of cardiovascular disease. Arch Intern Med 1999; 159:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/44\">",
"      Mondul AM, Rodriguez C, Jacobs EJ, Calle EE. Age at natural menopause and cause-specific mortality. Am J Epidemiol 2005; 162:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/45\">",
"      Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007; 69:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/46\">",
"      Rocca WA, Grossardt BR, Maraganore DM. The long-term effects of oophorectomy on cognitive and motor aging are age dependent. Neurodegener Dis 2008; 5:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/47\">",
"      Hogervorst E, Bandelow S. Sex steroids to maintain cognitive function in women after the menopause: a meta-analyses of treatment trials. Maturitas 2010; 66:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/48\">",
"      Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 2008; 70:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/49\">",
"      Shoupe D, Parker WH, Broder MS, et al. Elective oophorectomy for benign gynecological disorders. Menopause 2007; 14:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/50\">",
"      Gibson CJ, Joffe H, Bromberger JT, et al. Mood symptoms after natural menopause and hysterectomy with and without bilateral oophorectomy among women in midlife. Obstet Gynecol 2012; 119:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/51\">",
"      Nathorst-B&ouml;&ouml;s J, von Schoultz B, Carlstr&ouml;m K. Elective ovarian removal and estrogen replacement therapy--effects on sexual life, psychological well-being and androgen status. J Psychosom Obstet Gynaecol 1993; 14:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/52\">",
"      Aziz A, Bergquist C, Nordholm L, et al. Prophylactic oophorectomy at elective hysterectomy. Effects on psychological well-being at 1-year follow-up and its correlations to sexuality. Maturitas 2005; 51:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/53\">",
"      Dennerstein L, Koochaki P, Barton I, Graziottin A. Hypoactive sexual desire disorder in menopausal women: a survey of Western European women. J Sex Med 2006; 3:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/54\">",
"      Shifren JL, Monz BU, Russo PA, et al. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol 2008; 112:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/55\">",
"      Aziz A, Br&auml;nnstr&ouml;m M, Bergquist C, Silfverstolpe G. Perimenopausal androgen decline after oophorectomy does not influence sexuality or psychological well-being. Fertil Steril 2005; 83:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/56\">",
"      Aziz A, Bergquist C, Br&auml;nnstr&ouml;m M, et al. Differences in aspects of personality and sexuality between perimenopausal women making different choices regarding prophylactic oophorectomy at elective hysterectomy. Acta Obstet Gynecol Scand 2005; 84:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/57\">",
"      Shifren JL, Avis NE. Surgical menopause: effects on psychological well-being and sexuality. Menopause 2007; 14:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/58\">",
"      Rodr&iacute;guez MC, Chedraui P, Schwager G, et al. Assessment of sexuality after hysterectomy using the Female Sexual Function Index. J Obstet Gynaecol 2012; 32:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/59\">",
"      Melton LJ 3rd, Khosla S, Malkasian GD, et al. Fracture risk after bilateral oophorectomy in elderly women. J Bone Miner Res 2003; 18:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/60\">",
"      Parker WH, Broder MS, Liu Z, et al. Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol 2005; 106:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/61\">",
"      Vitonis AF, Titus-Ernstoff L, Cramer DW. Assessing ovarian cancer risk when considering elective oophorectomy at the time of hysterectomy. Obstet Gynecol 2011; 117:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/62\">",
"      North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010; 17:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/63\">",
"      Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010; 95:s1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/64\">",
"      Vujovic S, Brincat M, Erel T, et al. EMAS position statement: Managing women with premature ovarian failure. Maturitas 2010; 67:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/65\">",
"      Eliassen AH, Missmer SA, Tworoger SS, et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 2006; 98:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/21/15706/abstract/66\">",
"      Shufelt CL, Braunstein GD. Safety of testosterone use in women. Maturitas 2009; 63:63.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14198 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-F708DC0240-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_21_15706=[""].join("\n");
var outline_f15_21_15706=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21231476\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21231548\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12797502\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21231334\">",
"      SURGICAL EFFECTS ON OVARIAN FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12798786\">",
"      Surgical menopause",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12798793\">",
"      Early menopause following hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24792659\">",
"      INDICATIONS FOR OOPHORECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1235559\">",
"      STUDIES REGARDING ELECTIVE OOPHORECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24792980\">",
"      BENEFITS OF ELECTIVE OOPHORECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24793011\">",
"      Ovarian cancer risk reduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8214654\">",
"      - Alternatives to BSO for ovarian cancer risk reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8214361\">",
"      Breast cancer risk reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24793003\">",
"      Avoiding the need for subsequent oophorectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24792988\">",
"      RISKS OF ELECTIVE OOPHORECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24792996\">",
"      Added surgical risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21231420\">",
"      Long-term health risks",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H325404\">",
"      - All-cause mortality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21231434\">",
"      - Cardiovascular disease and stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21231441\">",
"      - Cognitive function and neurologic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21231462\">",
"      - Depression and anxiety",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H326764\">",
"      - Sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H326484\">",
"      - Osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8214913\">",
"      CLINICAL DECISION-MAKING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21231469\">",
"      ESTROGEN THERAPY AFTER OOPHORECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21231476\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/14198\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/14198|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/0/2049\" title=\"figure 1\">",
"      Lynch syndrome cancer risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/14198|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/40/7821\" title=\"table 1\">",
"      Cancer risks BRCA1 and BRCA2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/59/12221\" title=\"table 2\">",
"      Risk factors ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/49/42779\" title=\"table 3\">",
"      Risk assess crit breast ovar CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/37/3675\" title=\"table 4\">",
"      Revised Amsterdam criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/46/32490?source=related_link\">",
"      Abdominal hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44761?source=related_link\">",
"      Clinical manifestations and diagnosis of menopause",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28570?source=related_link\">",
"      Determinants and management of cardiovascular risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18233?source=related_link\">",
"      Endometrial and ovarian cancer screening and prevention in women with Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25978?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=related_link\">",
"      Epithelial ovarian cancer: Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/63/41975?source=related_link\">",
"      Estrogen and cognitive function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/60/5064?source=related_link\">",
"      Genetic risk assessment for individuals at risk for hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43560?source=related_link\">",
"      Management and complications of tuboovarian abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17418?source=related_link\">",
"      Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37880?source=related_link\">",
"      Management of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12393?source=related_link\">",
"      Oophorectomy and ovarian cystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14810?source=related_link\">",
"      Overview of the treatment of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=related_link\">",
"      Postmenopausal hormone therapy and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34202?source=related_link\">",
"      Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25258?source=related_link\">",
"      Sexual dysfunction in women: Epidemiology, risk factors, and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34985?source=related_link\">",
"      Sexual dysfunction in women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35401?source=related_link\">",
"      Vaginal hysterectomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_21_15707="Animal dander avoidance steps";
var content_f15_21_15707=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Avoidance measures for animal dander",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Removing animals from the house",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Keep animals outside, eg, in garage or kennel; restricting animals to certain rooms has not been shown to be effective.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Once animal has been removed, the premises should be cleaned thoroughly.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Controlling allergen with an animal in the house",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Difficult because the animal contains 10-50 mg of major allergen, while the quantities of airborne allergen are only 5-20 ng/m3. Using an air filter can only reduce airborne allergen.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Reduce reservoirs: remove carpets, reduce upholstered furniture to a minimum, replace drapes with blinds, or/and vacuum clean weekly using a vacuum with good filtration, ie, double thickness bags and/or HEPA filtration.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Room air filters: HEPA or electrostatic (maintenance data are better defined for HEPA).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Washing cats does not reduce allergen levels significantly. Washing dogs twice a week may help.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_21_15707=[""].join("\n");
var outline_f15_21_15707=null;
var title_f15_21_15708="Functions of medical interview";
var content_f15_21_15708=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F65802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=15\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F65802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=15\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Three functions of the medical interview",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Function 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Data gathering: Determine and monitor the nature of the problem.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Objectives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enable the clinician to establish a diagnosis or recommend further diagnostic procedures, suggest courses of treatment and predict the nature of the illness.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Function 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Relationship building: Develop, maintain, and conclude the therapeutic relationship.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Objectives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ensure patient's willingness to provide diagnostic information.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ensure relief of patient's physical and psychological distress.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ensure patient's willingness to accept the treatment plan or a process of negotiation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ensure patient and clinician satisfaction.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Function 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patient education: Carry out patient education and implementation of treatment plans.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Objectives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ensure patient's understanding of the nature of the illness.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ensure patient's understanding of suggested diagnostic procedures.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enhance patient's understanding of the treatment possibilities.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Achieve consensus between clinician and patient.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Achieve informed consent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Improve coping mechanisms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Promote lifestyle change.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Lipkin M, Putnam S, Lazare A. The Medical Interview, Springer-Verlag, New York 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_21_15708=[""].join("\n");
var outline_f15_21_15708=null;
var title_f15_21_15709="Dose response to diltiazem for rate control in AF";
var content_f15_21_15709=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80630&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80630&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dose response to diltiazem for rate control in atrial fibrillation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 245px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier analysis of the percentage of patients maintaining a therapeutic rate control response to each dose level of intravenous diltiazem infusion in patients who initially responded to bolus diltiazem. Maintenance of rate control was greater at doses of 10 to 15 mg/h.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Ellenbogen KA, Dias VC, Cardello FP, et al. Am J Cardiol 1995; 75:45.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_21_15709=[""].join("\n");
var outline_f15_21_15709=null;
var title_f15_21_15710="Contents: Infectious Diseases";
var content_f15_21_15710=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      Infectious Diseases",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Infectious Diseases",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     You receive the entire UpToDate library of specialties with your ",
"							subscription. Click on a section below to view a detailed list of topics associated ",
"							with that particular section. If you'd like to see the table of contents for other ",
"							specialties,",
"     <a href=\"UTD.htm?3/3/3134\">",
"      click here",
"     </a>",
"     .",
"     <br/>",
"     <br/>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?32/42/33454\">",
"         Antimicrobial drugs",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?32/3/32829\">",
"         Clinical microbiology review",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?3/49/3871\">",
"         CNS infections",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?42/26/43438\">",
"         Compromised host infections",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?21/33/22046\">",
"         Endocarditis and bacteremia",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?18/1/18463\">",
"         Fungal infections",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?4/50/4911\">",
"         Gastrointestinal infections",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?5/9/5278\">",
"         General ID issues",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?10/50/11054\">",
"         Global health",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?42/11/43198\">",
"         Gram negative rods",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?38/17/39198\">",
"         Gram positive cocci",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?20/54/21358\">",
"         Head and neck infections",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?3/24/3456\">",
"         Hepatitis",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?5/45/5842\">",
"         HIV infection",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?6/19/6463\">",
"         HIV treatment prevention",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?11/39/11897\">",
"         What's new in infectious diseases",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?37/48/38669\">",
"         Hospital acquired infections",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?33/6/33901\">",
"         ID calculators",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?19/10/19630\">",
"         Immunizations and travel",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?15/18/15663\">",
"         Immunodeficiency states non HIV",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?40/44/41677\">",
"         Infection control",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?1/53/1886\">",
"         Non TB mycobacterial infections",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?31/13/31966\">",
"         Other bacterial infections",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?19/20/19791\">",
"         Parasitic infections",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?5/43/5808\">",
"         Pulmonary infections",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?27/25/28062\">",
"         Sexually transmitted diseases",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?23/43/24254\">",
"         Skin soft tissue bone infection",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?18/59/19390\">",
"         Tick flea mite louse borne infections",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?35/30/36334\">",
"         Tuberculosis",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?42/37/43613\">",
"         Upper respiratory infections",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?15/54/16238\">",
"         Urinary tract infections",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?7/56/8065\">",
"         Viral infections (except HIV)",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"        &nbsp;",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"        <a class=\"tocItem\" href=\"UTD.htm?18/22/18798\">",
"         Patient Information",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-2589125723-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f15_21_15710=[""].join("\n");
var outline_f15_21_15710=null;
var title_f15_21_15711="FPLD type 2";
var content_f15_21_15711=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F60538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F60538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Patient with familial partial lipodystrophy type 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 603px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Familial partial lipodystrophy of the Dunnigan variety resulting from a missense mutation in the LMNA gene that encodes lamins A and C. Note the loss of fat from the extremities and trunk and excess accumulation of fat in the face and neck.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_21_15711=[""].join("\n");
var outline_f15_21_15711=null;
